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Summary
Hypertensive conditions of pregnancy, such as pre-eclampsia, are the principal direct
cause of maternal morbidity and mortality and affect up to 10% of first pregnancies
worldwide. The placenta is vital in the pathogenesis of pre-eclampsia since the
condition only occurs in the presence of placental tissue and the only cure is delivery
of the placenta and the fetus. It has been hypothesised that the placenta may be the
source of a circulating factor(s), which transports freely in the maternal system,
resulting in the multi-systemic and immunological responses that are characteristic of
pre-eclampsia. Among the potential "circulating" candidates currently being
investigated worldwide, is the tachykinin member, neurokinin B (NKB).
The aim of this project was to use a novel approach and investigate the role of
Neurokinin B in pre-eclampsia on a genetic level. This would be achieved by
bioinformatie characterisation of the neurokinin B (TAC3) and neurokinin B receptor
(TACR3) genes. Samples from thirty pre-eclampsia patients (of whom 10 also had
abruptio placentae) and twenty control individuals were used for mutation detection
analysis involving Multiphor gel electrophoresis and automated sequencing.
Three sequence variants were identified in the TAC3 gene and include: (i) 5' UTR
variant (-25 c-t); (ii) intronic variant IVS3-53 (t-g) and (iii) 3' UTR variant exon 7
(479, t-c). Only the -25 c-t variant had been reported before (SNP database). A
further two variants were identified in the TACR3 gene: (i) exon 3 variant (nt 857, a-t)
and (ii) 3' UTR variant, amplicon 5b (nt 1471, t-c), of which the latter had previously
been reported in the SNP database. In the analysis of allele and genotype frequencies,
only variant homozygosity for TAC3 -25 c-t could be associated with increased risk
of pre-eclampsia (RR 3.33, p=0.03). Follow-up work will include extended
genotyping in further stratified and larger patient cohorts and transfection studies to
assess splicing potential and functional consequences of the mutant alleles.
These data represent the first documented mutation screen of the TAC3 and TACR3
genes and report novel variants in patients with pre-eclampsia. This study contributes
to the knowledge of neurokinin B as a circulatory molecule and confirms the
heterogeneity of pre-eclampsia.
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Opsomming
Die belangrikste direkte oorsaak van moedersterftes is hipertensiewe toestande in
swangerskap, insluitende pre-eklampsie. Hierdie toestande kompliseer wêreldwyd
10% van alle swangerskappe. Die plasenta is kardinaal in die ontwikkeling van die
siekte aangesien dit slegs voorkom terwyl die plasenta in-situ is en die simptome
opklaar na verlossing van die plasenta. 'n Moontlike hipotese is dat die plasenta 'n
sirkuierende agens afskei wat in die moederlike sisteem beland en die uiteenlopende
multi-sistemiese simptome en tekens van die siekte veroorsaak, asook aktivering van
die immuunsisteem. Een van die moontlike kandidate wat tans wêreldwyd ondersoek
word as moontlike sirkuierende agens, is Neurokinien B (NKB), 'n lid van die
Tachikinien familie.
Die unieke benadering van hierdie projek was om die rol van Neurokinien B in pre-
eklampsie te ondersoek op 'n genetiese grondslag. Dit is bereik deur bio-informatiewe
karakterisering van die neurokinien B (TAC3) en neurokinien B reseptor (TACR3) en
deur mutasie sifting op DNA monsters van 30 pasiënte met pre-eklampsie (waarvan
10 ook abruptio placentae gehad het) en twintig kontrole individue met behulp van
Multiphor gel elektroforese en ge-outomatiseerde volgorde bepaling.
Drie volgorde variasies is geïdentifiseer in die TAC3 geen en sluit in: (i) 5' UTR
variant (-25 c-t); (ii) introniese variant IVS3-53 (t-g) en (iii) 3' UTR variant in ekson
7 (479, t-e). Slegs die -25 c-t variasie is voorheen raporteer (SNP databasis). Nog
twee variante is ook gevind in die TACR3 geen: (i) ekson 3 variant (nt 857, a-t) en (ii)
3' UTR variant, amplikon 5b (nt 1471, t-e); hierdie laaste een is al in die SNP
databasis raporteer. In 'n analise van genotipe en allele frekwensies is slegs
homosigositeit vir variant TAC3 -25 c-t geassosieër met 'n verhoogde risiko vir pre-
eklampsie (RR 3.33, p=0.03). Verdere werk sal nou fokus op die genotipering van
groter en gestratifiseerde pasiënt kohorte en transfeksie studies om splitsing potensiaal
en funksionele gevolge van mutante allele te ondersoek.
Hierdie data is die eerste gedokumenteerde mutasie sifting van die TAC3 en TACR3
gene en verslag word gelewer van unieke variasies in pasiënte met pre-eklampsie.
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Chapter 1
Introduction
1.1 Normal Pregnancy
Human pregnancy is a remarkable expenence with overwhelming emotions and
immense expectations from the expectant parents and also society at large. The
normal mean duration of human singleton pregnancy is 40 weeks (280 days) from the
first day of the last menstrual period (Gabbe et al., 2002). The period of gestation can
also be divided into three units of three calendar months each, or three trimesters,
since important obstetrical milestones can be designated by trimesters (Cunningham
et al., 2001). A fetus would be considered mature enough for birth at 34 weeks due to
lung maturity. According to South African law, a fetus is considered to be viable at 28
weeks gestation. However, by First World standards, an infant of 24 weeks gestation
may be expected to survive when extensive life-support and intensive care facilities
are available.
1.2 Morphological Growth
Fertilisation of the human ovum by a spermatozoan occurs in the fallopian tube within
hours after ovulation. The structure of the matured ovum is now referred to as the
zygote. The fertilised zygote then undergoes several phases of cleavage resulting in
the formation of the blastocyst. This process occurs in the first two weeks after
fertilisation and is followed by the embryonic period starting at week three. At the end
of this period, the heart is completely formed, the fingers and toes are present, the
upper lip is complete and the external ears are being formed. At around eight weeks
after fertilisation, the fetal period begins. During this developmental stage, a major
portion of lung development occurs, however, this gestational period consists mainly
of growth and maturation of the structures that were formed during the embryonic
period. Term is reached at 40 weeks gestation when the fetus is fully developed and
has a weight of approximately 3400g (Cunningham et al., 2001). In South Africa,
according to a study by Theron and Thompson (1995), analysing birth weight at the
1
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Tygerberg Hospital (Western Cape Province), the mean birth weight determined for
the hospital population was 2995g with a range of 760 - 5080g. The authors
established a weight-for-gestational-age centile chart specific for the population
served by the Tygerberg Hospital obstetric service (Appendix A).
It is with this fundamental knowledge of the miracle of pregnancy that one tries to
envisage the expectations of the parents-to-be, but more specifically the mother. This
sensitive development process may undergo problems at a myriad of stages, resulting
in complications of pregnancy.
1.3 Global Maternal Mortality
According to the World Health Organization (WHO), an estimated 210 million
women become pregnant every year. Approximately 30 million (~15%) of these
women develop complications, of which 1.7% is fatal.
(http://www.who.int/ reproductive-health).
A direct obstetric death is a death resulting from obstetric complications of
pregnancy, labour, or the puerperium. Direct obstetric deaths arise from six major
areas: hypertensive diseases of pregnancy, haemorrhage, infections/sepsis,
thromboembolism and in developing countries, neglected obstructed labour and
complications from illegal abortion. Other causes of direct obstetric deaths include
ectopic pregnancy, complications of anaesthesia and amniotic fluid embolism.
Maternal mortality is estimated at >600 000 maternal deaths worldwide per year from
pregnancy - related conditions. A striking analogy would be to imagine six jumbo jet
crashes per day, resulting in the deaths of all 250 passengers on board; all of these
passengers being women in their reproductive years oflife (Gabbe et al., 2002).
According to the WHO, every minute a woman dies from complications related to
pregnancy and childbirth. In other words, 1600 deaths every day. What is more cause
for concern is that 99% of these deaths occur in developing countries
(http://www .who .intire productive- health).
2
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Due to this high incidence of maternal deaths, an estimated one million children are
left motherless each year. These children are three to ten times more likely to die
within two years than children who live with both parents
(http://Vvww.who.intlreproductive-health).
According to WHO, pre-eclampsia accounts for about 12% of all maternal deaths.
More shockingly, in the least developed countries, it can cause complications in an
estimated 50 000 deliveries per year. In the more industrialised countries
approximately 15% preterm deliveries are induced due to pre-eclampsia
(http://www.who.intlreproductive-health).
1.4 Pregnancy Statistics in South Africa
South Africa has an estimated birth rate in excess of 1 million births per year. Recent
findings by WHO state that the highest maternal mortality rates are in sub-Saharan
Africa, where a woman has a one in sixteen chance of dying in pregnancy or
childbirth. In black South Africans, hypertension in pregnancy affects 18% of all
pregnancies (Chikosi et al., 1999).
The maternal mortality ratio (MMR) is the number of women that die as a result of
pregnancy, birth or within the first 42 days after delivery or termination of pregnancy
per 100 000 livebirths during that year. This figure is estimated to be in the vicinity of
175-200/100 000 livebirths in South Africa and 38/100 000 livebirths for the Western
Cape (NCCEMD, 2001). This ratio varies from province to province, with the figure
for Gauteng 67.4 in 100 000 livebirths and Free State 135 in 100 000 livebirths
(Cronjé and Grobler, 2003). During the triennium, 1999-2001, the National Health
Department reported 507 deaths associated with hypertensive disorders of pregnancy
in South Africa. This constituted 20.7% of all maternal deaths in the country. Of
these, 139 deaths were reported to be due to pre-eclampsia. Thus, in this triermium,
hypertensive deaths in mothers constituted the second most common cause of death
(Moodley and Molefe, 2001), second only to HIV/AIDS.
3
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Since the setting of this study is Tygerberg Hospital in the Western Cape Province, a
closer look at a study conducted by Hall et al. (2000), over the five year period (April
1992 - March 1997), indicated that 33 832 women delivered their babies at this
referral centre (approximately 6 766 births per year). In a more recent survey
conducted at the Tygerberg Hospital, between 1 May 2000 and 30 April 2001, 4 735
births above
500g were recorded (Hall, personal communication). With an incidence of
hypertensive conditions occurring in 10% of these tertiary referral cases, 470 cases of
pre-eclampsia (more than 1 patient per day), are expected at one institution alone. A
personal communication revealed that during the time period 1 May 2000 - 30 April
2001, 169 early onset pre-eclampsia patients (20-34 weeks gestation), had been
admitted to Tygerberg Hospital.
1.5 Maternal Adaptation to Pregnancy
The anatomical, biochemical and physiological adaptations of the pregnant woman
are profound. Many of these changes start soon after fertilisation and continue
throughout gestation in response to fetal stimulation (Cunningham et al., 2001). Some
of the changes relevant to this study will be dealt with briefly.
During normal pregnancy the total circulating blood volume increases by
approximately 45%, a process modulated by the interaction of the fetal (paternal)
allograft with the maternal tissue (Zeeman and Dekker, 1992). This increase refers to
both red blood cell mass and plasma volume and consequently a rise of 30-40% in
cardiac output occurs. This increase is the result of an increase in both the heart rate
and stroke volume. The heart rate increases on average by 15-20 beats per minute and
the stroke volume by 5-1Oml/min. A decrease in the arterial blood pressure arises with
an average decrease in systolic pressure of 5-10mmHg and a decrease in diastolic
pressure of 10-15mmHg (Cronjé and Grobler, 2003). As arterial pressure is
determined by the peripheral resistance as well as the cardiac output, a decrease in
peripheral vascular resistance must take place. The developing placenta is still too
small in the first trimester to account for this decrease. The reduced peripheral
resistance is most likely modulated by prostaglandins and nitric oxide and is also
4
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associated with an arterial refractoriness to the constricting actions of infused
angiotensin II (de Swiet, 1995). A failure of this expansion in plasma volume is
associated with an increase in the incidence of hypertension and intrauterine growth
restriction (Thorburn, 1994).
The kidneys enlarge during pregnancy as renal flow is increased by approximately
40% by 20 weeks gestation and with a further 10% thereafter. A decrease in plasma
sodium concentration occurs due to a much greater re-absorption of water compared
to sodium.
1.6 The Placenta
The placenta is a specialised organ of exchange, located at the interface between the
fetal and maternal circulations. This interface (placental syncytiotrophoblast)
compnses a multi-nucleated true syncytium with an extensive microvillus brush
border that is in direct contact with maternal blood (Thorburn et al., 1994). The
maternal surface is composed of chorionic villi, arranged in cotyledons (lobules) that
are separated by furrows. The maternal blood gives it a bluish-red colour and the
surface is covered by a thin layer of trophoblastic cells. The fetal surface on the other
hand, is smooth and shiny and the branches of the umbilical veins and arteries and the
umbilical cord protrude from it (Myles, 1985).
1.7 Functions of the Placenta
The placenta provides nutrients and oxygen to the fetus and excretes waste products
from the fetus. The placenta plays an essential role in the synthesis and transformation
of a variety of hormones necessary for the normal maintenance of pregnancy and
preparation for lactation (Thorburn et al., 1994). The placenta and the fetus therefore,
function as a unit and the fetus is dependent on the placenta for its quality of life in
utero (Myles, 1985). The main functions of the placenta are thus:
(i) Nutrition;
(ii) Respiration;
(iii) Excretion;
5
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(iv) Endocrine.
During the embryonic period, the placenta develops from a highly vascularised
membrane known as the chorion. The development of the placenta is largely
dependent on the successful attachment of the blastocyst to the uterine endometrium
(Redman et al., 1993).
1.8 The Decidua
The decidua refers to the functional layer of the endometrium of a pregnant woman.
This layer comprises of three sections namely:
(i) decidua basalis: the part of the decidua that forms the maternal part of the
placenta;
(ii) decidua capsularis: the superficial part of the decidua overlying the conceptus;
and
(iii) decidua parietalis: all the remaining parts of the decidua.
In normal pregnancy the spiral arteries increase in diameter by four- to six fold
compared with the non-pregnant state. The endothelium, internal elastic lamina and
smooth muscle layer is replaced by trophoblast and amorphous fibrin-containing
matrix.
6
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1.9 The Mature Placenta
The mature placenta is discoid and flattened in shape and weighs approximately SOOg
at birth. Figure I depicts a schematic cross-section through a mature placenta,
indicating the fetal and maternal circulations. It is about 20cm in diameter and 2.Scm
thick at the centre. The placenta is normally positioned in the upper part (fundus) of
the uterus (England, 1996).
Placental ischemia is a possible reason for widespread activation of the maternal
vascular endothelium that results in the enhanced formation of endothelin,
thromboxane, increased vascular sensitivity to angiotensin II and decreased formation
of vasodilators such as nitric oxide and prostacyc1in (Slowinski et al., 2002).
Maternal circulation
uteri ne arte
Figure I: Schematic view of a section through a mature placenta (not drawn to
scale). Adapted from Cunningham et al., 2001.
7
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1.10 Conditions ofthe Placenta
Since two particular pathological conditions of the placenta are significant to this
study, a short description of each is given. They are complete hydatidiform mole
(molar pregnancy) and abruptio placentae.
1.10.1 Complete Hydatidiform mole
Hydatid means 'drop of water' and mole means 'spot' (Figure II). Hydatidiform mole
is a mass of vesicles resulting in the cystic proliferation of the chorionic epithelium.
The chorionic villi form these vesicles which can vary in size from a pin-head to a
small grape. The embryo is absent and the karyotype is usually 46,XX but with all
genetic material of paternal origin (Kajii and Ohama, 1977). This karyotype is a result
of duplication of a paternal haploid set in a functionally empty ovum (Matsuda and
Wake, 2003). These molar pregnancies are more common in younger (under 20 years)
and older (over the age of 45) women. Interestingly, pre-eclampsia is observed in
~25% of women with complete hydatidiform mole.
Figure II: Schematic representation of a Hydatidiform Mole (not drawn to
scale). Adapted from Garrey et al., 1972.
8
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1.10.2Abruptio Placentae
Selected Cases of
Abruptio Placentae
Figure III: Schematic representation of Abruptio Placentae (not to scale).
Adapted from Young, 2002.
Abruptio placentae is a major complication of hypertensive disease in pregnancy
(Odendaal et al., 2000). It involves the premature separation of a normally-situated
placenta resulting in haemorrhage from the decidua basalis, with bleeding between the
placenta and the uterine wall (Figure III). This dangerous and unpredictable condition
occurs in 0.5-2% of pregnancies and in 25-30% of cases, results in fetal death. No
specific cause for abruptio placentae has yet been found, although it is associated with
many clinical conditions (Odendaal and Gebhardt, 1999). These include: pre-
eclampsia, homocysteinaemia, cigarette smoking, cocaine abuse, pre-labour rupture of
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the membranes and chorio-amnionitis (Cronjé and Grobler, 2003). Other factors such
as advanced maternal age, grand multiparity, polyhydromnios and previous history of
placental abruption have also been reportedtAnanth et al., 1996).
De Jong et al. (1997), reported a study which investigated the role of nutrition in the
development of abruptio placentae in the Western Cape population. Although no
nutritional anomaly could be found in the study group, the mean birth weight in the
abruptio placentae group was lower than the control group of similar gestation. It was
concluded that abruptio placentae was possibly a disorder of poor placentation and
that poor vitamin B6 status could be the aggravating factor in susceptible patients.
In 2000, Hall et al. and Odendaal et al. each indicated that 20.2% of patients
hospitalised for early onset, severe pre-eclampsia developed abruptio placentae.
Abruptio placentae has been implicated as a major cause of intra-uterine death in
South African hospitals (Odendaal, 1991; 1994). The perinatal mortality rate
associated with abruptio placentae ranges from 119 per 1000 to 580 per 1000
(Odendaal et al., 2000).
1.11 The Endothelium
The endothelium is a single cell layer that lines the internal surface of all blood
vessels (de Swiet et al., 2002). The endothelial cells have a very important metabolic
and secretory function to help maintain homeostasis in pregnancy. Any alteration in
the endothelial cell function results in an increased sensitivity to pressor agents,
reduced plasma volume and the activation of the coagulation cascade.
Normal endothelial cells modify the contractile response of adjacent smooth muscle
cells by the secretion of vasoconstrictors like (i) endothelin and (ii) angiotensin and
vasodilators like (iii) nitric oxide (NO) and (iv) prostacyclin (PGI2) (Wilkinson et al.,
1996).
10
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(i) Endothelin
Endothelin is a 21-amino acid peptide vasoconstrictor that is derived from a 23-
amino acid peptide precursor pre-proendothelin that is cleaved after translation to
form pro-endothelin. A converting enzyme then cleaves proendothelin to produce
the 21-amino acid endothelin. Endothelin exerts its vasoconstricting effects via
endothelin A receptors on the vascular smooth muscle. The endothelin B receptors
enable endothelin to release NO and PGh from the endothelium, thereby
inhibiting platelet activation (Granger et al., 2001). The endothelin system has
been shown to be activated in pre-eclamptic pregnancies since endothelin
concentrations are significantly higher than in non-pre-eclamptic pregnancies
(Slowinski et al., 2002).
(ii) Angiotensin II
The renin-angiotensin system is involved in the regulation of blood pressure and
electrolyte metabolism. Angiotensinogen is a u2-globulin produced in the liver and
is a substrate for renin. Renin is an enzyme produced in the juxtaglomerular cells
of the kidney that acts upon angiotensinogen to produce the decapeptide,
angiotensin 1. Two carboxyl terminal amino acids of angiotensin I are then
removed by angiotensin converting enzyme (ACE), a glycoprotein found in lungs,
endothelial cells and plasma to form angiotensin II. Angiotensin II is a potent
vasoconstrictor that increases the blood pressure by its action on the arterioles
(Murray et al., 1996).
(iii) Nitric Oxide (NO)
NO is an organic free-radical that is synthesised from L-arginine by a family of
enzymes known as NO synthases (NOS) (Granger et al., 2001). NOS exists in
both a constitutive (calcium-dependent) and inducible (calcium-independent) form
(Norris et al., 1999). Human endothelial NOS is widely distributed in placental
tissue and a reduction in placental NOS activity has been demonstrated in pre-
eclamptic placentae (Guo et al., 1999). NO reduces platelet sensitivity to pro-
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aggregatory agents, thus inhibiting platelet aggregation (Wilkinson et al., 1996).
In women developing pre-eclampsia, NO generation was shown to be reduced.
Inhibition of NO synthesis in rats during pregnancy produces hypertension and
proteinuria, making the endothelial NO synthase (eNOS) gene a primary candidate
for pre-eclampsia (Arngrimsson et al., 1997).
(iv) Prostacyclin (PGI2)
Prostacyclin is an endothelial-derived prostanoid which is synthesized from
arachidonic acid. It is a potent vasodilator, an inhibitor of platelet aggregation and
a stimulator of renin secretion (Lyall and Greer, 1996 and Wilkinson et al., 1996).
In normal pregnancy, the placenta produces approximately equal amounts of
prostacyclin and the vasoconstrictor, thromboxane. However, in pre-eclampsia,
the placenta produces in excess of seven times more thromboxane than
prostacyclin (Walsh, 1985). Cyclooxygenase metabolises prostaglandins, and
aspirin has been found to be an inhibitor of cyclooxygenase (Merviel et al., 2004).
Therefore, 75-100mg aspirin per day is sometimes prescribed to patients with a
history of early-onset, severe pre-eclampsia from about 8 weeks gestation of the
following pregnancy. This is thought to diminish the excess thromboxane and thus
re-establishes the PGI2/TXA2 balance. This role of aspirin in reducing the risk for
severe early-onset pre-eclampsia was first examined in a randomised way in the
CLASP (Collabarative Low dose Aspirin Study in Pregnancy) trial (CLASP
Collaborative Group, 1994). A subsequent study by Bower et al. (1996),
confirmed that low dose aspirin therapy was effective in significantly reducing the
incidence of pre-eclampsia.
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Chapter 2
Pre-eclampsia
Hypertensive conditions of pregnancy, including pre-eclampsia, are the principal
direct cause of maternal morbidity and mortality, affecting 5-10% of first pregnancies
worldwide (Page et al., 2000). One in six stillbirths can be associated with
hypertensive disorders (Wareing et al., 1993 and Prins et al., 1997).
Hypertension can exist prior to pregnancy (essential hypertension) or it can be
induced by pregnancy (pregnancy-induced hypertension). Pregnancy-induced
hypertension is defined as a diastolic pressure of 2:90 mmHg or an increment of 2:20
mmHg from the first trimester diastolic blood pressure measurement. The absolute
blood pressure levels have to be observed on two occasions, 2:4 hours apart. This form
of hypertension can be accompanied by significant proteinuria (2:300 mg protein per
24 hours urine collection) (Dekker et al., 1995), coagulopathy and peripheral and
cerebral oedema when it is then referred to as pre-eclampsia. Pre-eclampsia may
swiftly become more complicated and affect the maternal liver, kidneys, lungs, blood
vessels and nervous system. These clinical problems only become apparent in the
second half of the pregnancy even though they are believed to start during the first
trimester (Page and Lowry, 2001).
Pre-eclampsia is a condition unique to human pregnancy and can lead to iatrogenic
prematurity. It had been termed the "disease of theories" by Zweifel as early as 1916
(Walker and Gant, 1997), since several models for its pathogenesis have been
proposed. However, no single hypothesis has yet been shown to comprehensively
define the disorder (Luttun and Carmeliet, 2003). A current theory proposes a two-
stage model in the development of the condition. The first stage appears to involve the
defective trophoblastic invasion of the placental bed, which results in hypoperfusion
and an ischemic placenta. The second stage then appears to involve the release of an
unknown factor(s) into the maternal circulation from the placenta in response to the
first stage (Page and Lowry, 2001). Various factors have been named as likely
candidates, including neurokinin B (NKB), vascular endothelial growth factor
(VEGF) and placental growth factor (PIGF).
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2.1 Pathophysiology of pre-eclampsia
Recent work has indicated that a key feature of placental pathology is an insufficient
uteroplacental circulation which leads to placental hypoxia and oxidative stress. More
severe cases result in infarction (Redman and Sargent, 2003).
Trophoblast cells normally grow from villi of the early placenta into the spiral
arteries of the maternal decidua, thereby displacing the muscular layer of arteries. The
cytotrophoblast secretes enzymes (Gelatinase A and B) to digest the extracellular
matrix of the endometrium (Bischof, 2001). These enzymes are also called matrix
metalloproteinases (MMP) (MMP2 and MMP9, respectively). After replacement of
the muscular (and vasopressor-responsive) media with vasopressor-inert trophoblast
cells, the arterioles now allow an increased flow of blood to the intervillous space.
These changes extend from the intervillous space to the inner-third of the
myometrium.
In pre-eclampsia, however, this process of trophoblastic invasion occurs to a lesser
extent (or not at all), resulting in narrower vessels and ultimately in placental
insufficiency and fetal growth impairment (Cronjé and Grobler, 2003). Furthermore,
the spiral artery dilation is only -40% of that of normal pregnancy. The myometrial
component of the spiral artery is not invaded by trophoblast and is therefore unaltered
from the non-pregnant state. Ultimately, almost half of the decidual portion of the
spiral arteries in women with pre-eclampsia exhibit acute atherosis.
Trophoblast invasion by MMP2 and MMP9 is mediated by several autocrine factors
(such as human chorionic gonadotrophins and leptin secreted by the trophoblast) as
well as in a paracrine way by uterine factors (such as tumor necrosis factor and
interleukins). It is possible that disruption of these early response genes may be the
earliest insult leading to defective placentation (Bischof, 2001). This defective
trophoblastic invasion leads to vascular damage with increased endothelial
permeability. Normal endothelial cells modulate complex actions like immune and
inflammatory responses, maintenance of vascular integrity and anticoagulant effects.
However, in pre-eclampsia, where these endothelial cells become damaged, they lose
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their normal function and start to produce vasoconstrictors (Cronjé and Grobler,
2003).
Van Beek et al. (1998) have hypothesised that the formation of oxygen-free radicals
caused by immune maladaptation, results in the activation of lymphoid cells and an
ischemic placenta. When the production of these free radicals exceeds the
neutralization capacity of the free radical scavengers, a condition of imbalance is
created which favours the formation of lipid peroxides from unsaturated fatty acids.
The oxygen-free radicals together with the lipid peroxides are toxic to endothelial
cells and is another possible contributor to the pathophysiology of pre-eclampsia.
Normal pregnancy Maternal blood
Factors
Platelet/coagulation
( ~w,oo~
Maternal circulation
Pre-eclampsia
Endothelial Neutrophild.miT~"'''ti'"
Hypertension
Myometrium Decidua Placental villi
Figure IV: Schematic representation of trophoblastic invasion of spiral arteries.
Dotted lines indicate trophoblast invading the vessels. Adapted from Lyall and
Greer, 1996).
Pre-eclampsia has been reported in abdominal pregnancies, therefore a uterine cause
has been eliminated and it has also been shown that the presence of a fetus is not
essential, since pre-eclampsia is characteristic of molar pregnancies (Wilkinson et al.,
15
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1996). It has been proposed that placental tissue is probably vital to the pathogenesis
of pre-eclampsia as this condition only occurs if the placenta is present and the only
cure is the delivery of the fetus and placenta (Wareing et al., 2003).
2.2 HELLP Syndrome
Pre-eclampsia can be further complicated by accompanying HELLP (haemolysis,
~levated liver enzymes, low platelet) syndrome. In normal pregnancy, the platelet
count may drop to below 200x 109/L, because of the normal maternal blood volume
expansion. However, in pre-eclampsia, the platelet count can drop even further. This
drop is associated with the HELLP syndrome (Walker, 2000). Liver involvement in
pre-eclampsia is the cause of the epigastric pain commonly reported in severe pre-
eclampsia and results in swelling of the liver and stretching of the liver capsule. The
haemolysis is caused by the damaged endothelium. The incidence of HELLP
syndrome at Tygerberg is about 3% of severe pre-eclampsia cases and as high as 9%
in patients with abruptio placentae (Odendaal et al., 2000).
2.3 The Genetics of Pre-eclampsia
Various hypotheses have been proposed to explain the mode of inheritance of pre-
eclampsia, assuming that it does indeed have a genetic basis. In the 1980's, Chesley
and Cooper (1986) studied the sisters, daughters, granddaughters and daughters-in-
law of eclamptic women and concluded that pre-eclampsia was clearly heritable.
Recent reports have also established a familial predisposition to pre-eclampsia. Esplin
et al., 2001 proposed that since the fetal genotype is a combination of the maternal
and paternal genotypes, it may be important to determine the contribution of the fetal
and paternal components to the predisposition to pre-eclampsia. They found that men
and women who were the products of pregnancies complicated by pre-eclampsia were
significantly more likely to have pregnancies affected by pre-eclampsia. A
primigravida woman with a family history of pre-eclampsia was three times more
likely to develop pre-eclampsia during pregnancy than a primigravida woman without
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such a family history. Also, a man born of a pregnancy complicated by pre-eclampsia
is twice as likely to father a child from a pre-eclamptic pregnancy than a man who
was born of an uncomplicated pregnancy. Furtheremore, a man who had previously
fathered a child from a pre-eclamptic pregnancy, who then fathers a child with a
different partner, was twice as likely to have the latter pregnancy also complicated by
pre-eclampsia (Lie et al., 1998). Therefore, the role of the paternal and fetal genes and
their contribution to pre-eclampsia warrants further investigation.
2.3.1 Linkage Studies
In order to identify areas within the genome that may harbour pre-eclampsia causative
genes, a genome-wide linkage study was performed by Amgrimsson et al. (1999)
utilising the homogenous island population of Iceland. The data indicated a
chromosome 2p 13 locus (lod score 4.70), however, a closer look at the study group
revealed that these peaks were attributed mainly to the two larger families in the study
cohort. These data provide indirect evidence for the existence of several genes which
are likely to contribute to the clinical phenotype.
An independent genome scan carried out in families of Australian and New Zealand
descent (Moses et al., 2000), confirmed the presence of a chromosome 2 candidate
locus (LOD score 2.58, located between D2S112 and D2S151) and suggested an
additional locus on chromosome llq23 (LOD 2.02, located between DllS925 and
DIIS4151).
2.3.2 Candidate genes (case-control association studies)
The specific gene variants that have been investigated in pre-eclampsia include factor
V Leiden (GI691A) mutation in the factor V gene, the G20210A mutation in the
prothrombin gene, the M235T mutation in the angiotensinogen gene, the Glu298Asp
mutation in the eNOS gene and the C677T and A1298C mutations in the MTHFR
gene, among others.
Since pre-eclamptic women exhibit haematological (bleeding) abnormalities, genes
encoding factors involved in the coagulation cascade have been investigated. The
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factor V gene, which is located on chromosome 1, carries the G1691A (Leiden)
variant. This mutation results from the substitution of the normal guanine with an
adenine nucleotide at position 1691 of the factor V gene (Bertina et al., 1994). The
prothrombin mutation results from an adenine substitution for a guanine at position
20210 in the 3' UTR region of the prothrombin gene (O'Shaughnessy et al., 2001).
Several genes encoding "vascular" factors have been extensively investigated in pre-
eclampsia. The angiotensinogen gene is located on chromosome 1 and contains the
variant M235T that has been identified as a risk factor in some pre-eclamptic women
(Pipkin 1999). A missense Glu298Asp variant was identified in exon 7 of the eNOS
gene. This variant results from the substitution of an aspartate from the normal
glutamic acid residue (Yoshimura et al., 1998) and represents a risk factor for pre-
eclampsia in Japanese women.
Another common polymorphism is found in the methylenetetrahydrofolate reductase
(MTHFR) gene, namely the C677T variant, which is responsible for reduced MTHFR
activity. This polymorphism is a cytosine to thymine substitution at nucleotide
position 677, converting an alanine residue to a valine. The human MTHFR gene has
been mapped to chromosome 1p36.3 and catalyses the conversion of 5,10-MTHF to
5-MTHF, a co-substrate for homocysteine remethylation to methionine. Altered levels
of homocysteine are a recognised risk factor for cardiovascular disease and were
thought to contribute to the hypertension component of pre-eclampsia. MTHFR
variant C677T has been documented as a risk factor for the development of pre-
eclampsia (Prasmusinto et al., 2002).
It is apparent that several genes may be involved in the aetiology of pre-eclampsia,
and they may be population-restricted (Table I). For example, in a very recent
publication, the association of the factor V Leiden mutation with pre-eclampsia in the
Caucasian population has been reported to be rare in other ethnic groups (Prasmusinto
et al., 2004). Rosenberg et al. (2002) reported that the frequency of the MTHFR
C677T allele varies phenomenally in different regions of the world and across ethnic
groups. The allele frequency is 0.07 in sub-Saharan Africans and 0.06 in Canadian
Inuit, whereas in Caucasians, Japanese and Chinese, the allele frequencies are 0.24-
0.54 (Pepe et al., 1998). In keeping with this, Chikosi et al. (1999) reported that the
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polymorphic C677T mutation was not an important factor in the pathogenesis of pre-
eclampsia in black South African women.
Thus one concludes that the varying disease allele frequencies in different population
groups influence the pathogenesis of pre-eclampsia and so further contribute to the
complexity of the disease.
Table I: Summary table of some candidate gene studies (up to 2002) and their
association or lack of association with pre-eclampsia.
Gene Positive association with pre- No association with pre-
eclampsia eclampsia
AGT Ward et al. (1996) Morgan et al. (1994)
Arngrimsson et al. (1993) Wilton et al. (1995)
Takimoto et al. (1996) Guo et al. (1997)
Kobashi et al. (1999) Harrison et al. (1997)
Morgan et al. (1999) Arngrimsson et al. (1999)
Morgan et al. (1999) Suzuki et al. (1999)
Kobashi et al. (2001) Moses et al. (2000)
Hefler et al. (2001) Curnow et al. (2000)
Lachmeijer et al. (2001)
Bashford et al. (2001)
NOS3 Arngrimsson et al. (1997) Harrison et al. (1997)
Guo et al. (1999) Lewis et al. (1999)
Yoshimura et al. (2000) Arngrimsson et al. (1999)
Bashford et al. (2001) Lade et al. (1999)
Hefler et al. (2001)
Savvidou et al. (2001)
Kobashi et al. (2001)
Tempfer et al. (2001)
MTHFR Grandone et al. (1997) Powers et al. (1999)
Sohda et al. (1997) Chikosi et al. (1999)
Kupferrninc et al. (1999) O'Shaughnessy et al. (1999)
de Groot et al. (1999)
Kaiser et al. (2000)
Laivuori et al. (2000)
Kobashi et al. (2000)
Raijrnakers et al. (2001)
Kim et al. (2001)
Lachmeijer et al. (2001)
Livingston et al. (2001)
Ozcan et al. (2001)
Kaiser et al. (2001)
FVL Dizon-Townson et al. (1996) Lindqvist et al. (1998)
Brenneret al. (1996) Lindqvist et al. (1999)
Nagy et al. (1998) O'Shaugnessy et al. (1999)
Mimuro et al. (1998) de Groot et al. (1999)
Krauss et al. (1998) Van Pampus et al. (1999)
Nagy et al. (1998) Kim et al. (2001)
Kupferrninc et al. (1999) Livingston et al. (2001)
Rigo et al. (2000)
Ozcan et al. (2001)
Hillerrnann et al. (2002)..Adapted from Lachmeijer et al., 2002.
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2.3.3 Microarray Studies
Pre-eclampsia is undoubtedly a complex, multifactorial disease with several genes
involved in its aetiology. Microarray analysis was designed to enable relative
quantification of gene activity from a multitude of genes, simultaneously. Since this
technology is relatively 'new', not many studies have been reported yet.
One such DNA microarray study of pre-eclamptic tissue was reported by Reimer et
al. (2002). In this study nine categories of genes were differentiated, viz., adhesion
molecules, obesity-related genes, transcription factors/signalling molecules,
immunological factors, neuromediators, oncogenic factors, protease inhibitors,
hormones and growth factor-binding proteins. Amongst these, the obesity-related
genes were found to be most significantly associated with pre-eclampsia. The obese
(Ob) gene was found to be significantly up-regulated, and biochemically, elevated
leptin protein levels were measured.
Another microarray study by Pang and Xing (2003), found that 162 of221 cytokine-
associated genes were up-regulated in pre-eclamptic placentae. In the third of the four
studies reported to date, Tsoi et al. (2003), demonstrated glycogen phosphorylase to
be up-regulated in placentas from pre-eclamptic patients. In the most recent study by
Pang and Xing (2004), apoptosis-related genes were investigated and 35% were found
to be up-regulated in pre-eclamptic placentae.
2.4 Circulating factors
Since the delivery of the placenta results in the cessation of the symptoms associated
with pre-eclampsia, it is believed that the placenta may be the source of a circulating
factor(s) (Roberts et al., 1989). This factor(s) circulates freely in the maternal system
resulting in the multi systemic and immunological responses that are characteristic of
pre-eclampsia.
Potential candidates, identified largely on the basis of their expression profiles and
capacity to circulate within the maternal circulation, include neurokinin B, vascular
endothelial growth factor (VEGF), oxidative stress and lipid peroxidases,
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syncytiotrophoblast microvillus membranes (STMs) (Hayman, 2004) and placental
growth factor (PlGF) (Luttun and Carmeliet, 2003). Neurokinin B will now be
discussed in further detail in the quest to determine its role as such a circulating
factor.
2.5 Neurokinin B
Neurokinin B (NKB) belongs to a family ofneuropeptides called the tachykinins. The
first and most well known is substance P (SP) that was discovered in 1931 (von Euler
and Gaddum, 1931). In 1983, a further two members were designated neurokinin A
(NKA) and NKB. They are classified in the same family since they share a common
C-terminal sequence (Phe-XsGly-Leu-Met-Nl-lr), where X is hydrophobic. The N-
terminal region is believed to convey receptor specificity to each of the three known
mammalian tachykinin receptors. SP, NKA and NKB are encoded by two distinct
mRNAs derived from separate preprotachykinin (PPr) genes (Page et al., 2001).
PPT-A encodes the SPINKA gene which generates four mRNAs by alternate RNA
processing: u- and D-PPT mRNA, which encodes SP only, and P- and y-PPT mRNAs,
which encode both SP and NKA. The PPT-B gene generates only one mRNA that
produces NKB (Page et al., 2001).
2.5.1 The function of Neurokinin B
The tachykinins have been implicated in a variety of biological actions from smooth
muscle contraction, vasodilation, pain transmission and inflammation, to the
activation of the immune system (Longmore et al., 1997; Page et al., 2001).
2.5.2 The Neurokinin B gene
The human NKB / TAC3 gene expressed in the placenta, comprises seven exons and
spans a region of 5.4 kilobase (kb) pairs. Exons 1 and 7 correspond to the 5' and
3'untranslated regions of the mRNA, respectively (Page et al., 2001).
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5' 3'
Figure V: Schematic diagram of TAC3 gene (not drawn to scale)
2.5.3 Neurokinin B Receptors
The neurokinin B receptors are specific membrane receptors which belong to the
family of G protein-coupled receptors. Three receptors have been characterised,
namely, NKl, NK2, NK3. The genes encoding these are similar in structure and
contain five exons (Pennefather et al., 2004). Neurokinin B activates these receptors
with the following order of affinity: NKl: SP>NKA>NKB; NK2: NKA>NKB>SP;
NK3: NKB>NKA>SP, since SP shows preference for NKI, NKA for NK2 and NKB
forNK3.
2.5.3.1 The TACR3 Gene
5' 3'
Figure VI: Schematic diagram of TACR3 gene (not drawn to scale).
2.6 Neurokinin B in pre-eclampsia
In human pregnancy, the expression of NKB is confined to the outer
syncytiotrophoblast of the placenta and significant concentrations of NKB can be
detected in the plasma as early as the ninth gestational week (Page et al., 2000).
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These authors speculated that elevated levels of NKB in early pregnancy may be an
indicator of hypertension and pre-eclampsia.
However, Sakamoto et al., (2003) has shown that the concentration of NKB in early
pregnancy was not significantly different from that in the non-pregnant state, but that
the concentration ofNKB in the blood increased with an increase in gestational age.
This trend has been previously reported by Page et al., (2000) as well as D' Anna et
al., (2002). Schlembach et al., (2003), on the other hand, has shown that NKB serum
levels are higher in normotensive pregnant women than in pre-eclamptic pregnant
women.
Recent studies by Laliberte et al., (2004) have shown that contrary to the hypothesis
that neurokinin B constricts placental resistance vessels, it does in fact, cause
relaxation of isolated human placental resistance vessels.
Since biochemical determination of neurokinin B appears to be influenced by factors
such as gestational age, hormones and other vaso-active substances (Schlembach et
al., 2003), its role in normal pregnancy and in conditions like pre-eclampsia will
remain hampered. However, on the basis of localisation, expression and functions
(such as vasoconstriction, immune system activation, etc.), it remains a good
candidate gene for pre-eclampsia. An alternative form of measuring its candidacy is
therefore warranted.
Genetic genotypes are unvarying and independent of gestational age, health status,
etc., and can be correlated with both biochemical and clinical data.
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Chapter 3
Identification of Mutations
3.1 Mutation Screening Techniques
The underlying principle of a mutation detection assay is that the nucleotide sequence
of the gene in the affected individuals will differ from the sequence content of the
same gene in individuals with a normal phenotype (Pasternak, 1999). Several
mutation detection techniques have been developed, namely, single strand
conformational polymorphism (ssep), denaturing gradient gel electrophoresis
(DGGE), heteroduplex analysis (HA), chemical mismatch cleavage (Clvle), protein
truncation test (PTT) and direct DNA sequencing, among others.
3.1.1 Single Strand Conformational Polymorphism
Single strand conformational polymorphism is one of the most commonly used
methods of detecting mutations. Some, or all, of the exons of a gene are amplified
individually by peR of the affected and unaffected individuals. These peR products
are then denatured, rapidly cooled on ice, and resolved by gel electrophoresis. Each
denatured single stranded DNA molecule assumes a different three-dimensional
conformation and therefore migrates at a different rate on a gel during electrophoresis.
Therefore the difference between affected and unaffected individuals is easily
detected by direct comparison. The nature of the mutation can then be characterised
by direct sequencing. This method has limitations in that it can only detect about 90%
of the single base pair mutations in peR products that are 200bp or less (Orita et al.,
1989).
3.1.2 Denaturing Gradient Gel Electrophoresis
Denaturing gradient gel electrophoresis involves electrophoresis of peR products in
a polyacrylamide gel containing a gradient of two denaturants, viz. urea and
formamide. DNA fragments are separated according to their melting pattern. This
melting behaviour is highly sequence-dependent, therefore when a DNA molecule is
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partially melted it undergoes a conformational change and experiences a decrease in
electrophoretic mobility. Double-stranded DNA molecules that differ by even a single
base substitution show different melting behaviour, thus melting at a different position
along the gel. A critical step in this mutation detection technique is the introduction of
a GC-clamped primer that prevents the fragment from melting completely. This GC-
clamp also alters the melting characteristics of the fragment thereby allowing the
detection of mutations in the melted part of the fragment (Wu et al., 1998). This
method can detect more than 95% of the single base differences present in PCR
products that are 600bp or less, however it does demand meticulous technical skills
(Pasternak 1999), as it needs optimised experimental conditions for each DNA
fragment (Wu et al., 1998).
3.1.3 Heteroduplex Analysis
Heteroduplex analysis involves the amplification of DNA from two different sources
that differ by only a single nucleotide pair, with the same primers. The PCR products
are combined, denatured, and renatured. Homoduplex and heteroduplex DNA
molecules are formed and these molecules migrate at different rates through a gel.
This method can detect more than 95% of the single nucleotide mismatches in DNA
fragments of300bp or less (Keen et a!., 1991).
3.1.4 Chemical Mismatch Cleavage
Chemical mismatch cleavage is a variant of heteroduplex analysis. DNA samples are
amplified and one of these PCR products is radio labeled during amplification. The
PCR products are combined, heat-denatured, and then left at room temperature to
renature. These samples are then split into two aliquots. One aliquot is treated with
hydroxylamine hydrochloride and the other with osmium tetroxide. Each aliquot is
then treated with piperidine alkaloid, which cleaves the DNA strand at a modified
nucleotide. These samples are then resolved on a denaturing polyacrylamide gel and
viewed by autoradiography (Gunther, 1997). The presence of a heteroduplex, rather
than homoduplexes, indicates the presence of a sequence variant. This method detects
more than 95% of the single nucleotide mismatches in DNA fragments up to 1700bp
in length (Cotton et al., 1988).
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3.1.5 Protein Truncation Test
Protein truncation test is based on reverse transcriptase-PCR and targets mutations
that generate shortened proteins, mainly premature translation termination. Briefly,
RNA is reverse transcribed to generate a cDNA copy. This cDNA is then amplified
using PCR in combination with a specifically tailed F primer facilitating in vitro
transcription by T7-RNA polymerase. The products are then analysed on an agarose
gel to verify amplification, determine yield and also check the size. Abnormally
migrating products point to mutations (deletions, duplications, etc.). Lastly, in vitro
transcription/translation is used to generate peptide fragments. These are then
analysed on a SDS-PAGE gel in order to detect translation terminating mutations.
The advantages of this technique are that it pinpoints the site of a mutation, has good
sensitivity, has a low false-positive rate and it highlights any possible disease-causing
mutations. The technical problem is that it largely uses an RNA target and in order for
it to be used for high throughput, major improvement has to be made (Den Dunnen
and Ommen, 1999).
3.1.6 Direct DNA Sequencing
Direct DNA sequencing is employed to identify both known and unknown sequence
specific nucleotide variants. It has been termed the "gold standard" of mutation
detection techniques. Various automated systems are available, like the ABI 3100
automated DNA analyser (Applied Biosystems, USA). Each nucleotide base in a
DNA strand is differentially labelled by a fluorescein. When combined in a single
lane on a gel matrix, each fluorescein is excited at a particular wavelength when the
product passes through a laser beam, thus producing a distinct "peak" pattern, which
is subsequently read as "sequence".
Ultimately, the choice of method for mutation detection depends on the characteristics
of the genees) being screened and the availablilty of resources (eg, funding and staff).
The identification of a mutation would warrant further functional analysis and this
could facilitate the molecular and biochemical characterisation of the genetic defect.
Finally, this would result in more specifically targeted treatment/management of the
specific disorder/disease.
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Aim
The aim of this study is to establish (by molecular genetic techniques) whether
variants exist in the TAC3 and TACR3 genes, and if so, whether they are associated
with pre-eclampsia.
This can be achieved by mutation analysis of the novel TAC3 and TACR3 genes in a
clinically-defined pre-eclampsia cohort and a control panel.
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Chapter 4
Materials and Methods
4.1 Materials
4.1.1 Patient Selection
Institutional and ethical approval (C99/025) was granted for the project entitled
"Genetic Aspects of Pre-eclampsia" (GAP). Written consent was obtained from each
participant and a questionnaire was completed before blood was collected in EDTA
tubes. A copy of the consent form and questionnaire are included as Appendix B and
C, respectively.
The patients involved in this study were identified and recruited in the labour ward at
Tygerberg Hospital since 1999 and recruitment is ongoing. Participants were
restricted to a single ethnic group (South African Coloured) who represent the
majority of patients at this institution.
Since pre-eclampsia is a complex clinical condition, various criteria were applied in
the selection of patients for this study. The patients were assigned to various groups,
(A-H), based on distinct clinical criteria. See Appendix D for details of GAP
participants.
For the purposes of investigating the role of Neurokinin B in pre-eclampsia, a pilot
study was initiated which involved mutation analysis of the TAC3 and TACR3 genes
in a subset of GAP patients.
(i) Group 1: 20 controls (multigravidae) who had pregnancies uncomplicated
by hypertensive disease in the index and all other pregnancies;
(ii) Group 2: 20 primigravidae with onset of severe pre-eclampsia before 34
weeks gestation;
(iii) Group 3: 10 patients with pregnancy complicated abruptio placentae (with
or without the HELLP syndrome).
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Although this pilot study was restricted to 50 patients, any significant findings that
may be demonstrated could result in an extension of the project, to include the
other GAP patients.
4.1.2 Blood sampling
Following recruitment, a peripheral venous EDTA-preserved sample of maternal
blood was collected by a registered research nurse or the clinician on duty. Cord
blood was subsequently obtained during delivery. The fathers of the babies were
encouraged to participate as well, but unfortunately, due to varying circumstances,
they were largely absent.
4.2 Methods
4.2.1 DNA Extraction
DNA was extracted from the whole blood using the GENTRA ™ PureGene® genomic
DNA purification kit (Minneapolis, USA). Briefly, the O.3ml blood was first added to
an aliquot of red blood cell lysis solution, which lysed the red blood cells. Thereafter,
a second buffer solution was added to the sample to lyse the nucleated white blood
cells. This was followed by the addition of the protein precipitation solution that
resulted in the separation of aqueous DNA from proteins, which formed a pellet that
was discarded. The DNA was then precipitated from the remaining solution in
isopropanol. The DNA pellet was then washed with 70% ethanol before being
rehydrated with the DNA hydration solution and stored at 4°C until required.
4.2.2 Bioinformatics
Several databases were trawled and sequences relating to NKB and its receptor
documented. Intronlexon boundaries and regulatory domains were designated and the
novel TAC3 and TACR3 genes fully annotated using Locuslink at the NCBI (National
Center for Biotechnology Information), locus link (http://www.ncbi.nlm.nih.govQ
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(Appendices E and F). Primers were then designed
intronic regions usmg Primer3 at
binJprimer3/primer3 www.cgi(Rozen and Skaletsky,
for each exon and flanking
http://frado.wi.mit.edulcgi-
2000). This facilitated the
design of different sets of primers with common parameters such as melting
temperature, GC content and length. Primer specificity was verified by BLAST
(Basic Local Allignment Search Tool) : (http://www.ncbi.nlm.nih.gov/BLASTL)
(Altschul et al., 1990).
4.2.3 rca Amplification
The sequences, exon size, expected product size, predicted annealing temperature and
melting temperature used for the PCR amplification for all amplicons are summarised
in Table III. Each reaction was carried out in a total volume of 50111and consisted of:
5111lOx reaction buffer, 15pmol of each primer (Inqaba Biotec, RSA), 200llM dNTPs
(Invitrogen, USA), 3111MgCh (25mM), 0.11l1 Taq polymerase (5U/IlI) (Bioline
Biotaq, Celtic Diagnostics) and -iOOng genomic DNA as template.
The PCR thermal cycling (GeneAmp®PCR System 9700) for the TAC3 gene was
initiated at 95°C for 2 minutes, followed by 40 cycles of denaturation at 94°C for 30
seconds, annealing at 52°C (exon 1), 55°C (exons 2,4, 5,6, 7), 57°C (exon 3), for 15
seconds and extension at noc for 1 minute. A final extension step at noc for 5
minutes was carried out. The amplification was verified by resolving PCR products
on a 1.5% agarose gel containing ethidium bromide, visualised by UV
transillumination.
The TACR3 gene was amplified as described for the TAC3 gene above. However, the
annealing temperatures were as follows: 53°C (exon Ic), 55°C (exons la, 3, 5a, 5b);
59°C (exons 1b, 4) and 61"C (exon 2).
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4.2.4 Mutation Detection
Following confirmation of a peR product by agarose gel electrophoresis, an aliquot
of each sample was taken for Multiphor Gel Electrophoresis (Pharmacia LKP 2117
Multiphor Electrophoresis Unit, Pharmacia ).
4.2.4.1 Multiphor Electrophoresis System
The Multiphor Electrophoresis System combines single strand conformation
polymorphism and heteroduplex analysis. This method thus increases the detection
rate, allows for greater and very fast sample throughput and extends the range of
amplification analysis to 500-600bp fragments. The reaction conditions are the same
for all DNA fragments thereby recognising all classes of point mutations viz. base
substitutions, deletions and insertions. Therefore this assay provides rapid and
efficient screening without the use of dangerous compounds such as 32p. It also allows
for the ability to detect up to 97.5% of all point mutations in the coding region of a
disease gene (Liechti-Gallati et al., 1999).
4.2.4.1.1 Multiphor Methodology
The back plate (118mm x 220mm x 3mm) and the well plate (118mm x 220mm x
3mm) were wiped with ethanol three times each. The back plate was then vigorously
wiped with 87111plate glue, until some resistance was felt. Immediately thereafter, the
back plate was again wiped six to eight times with ethanol. The well plate was then
wiped 3 times with acetone, remembering to be gentle over the wells. The spacers
were laid down on the well plate and the plates were then sandwiched together with
clamps. The gel mix contained 5.3ml 6% PAGE mix, 8.5ml Tris formate buffer, 3ml
41% glycerol, 200Il110%APS and 20111TEMED. The gel was cast and allowed to set
for approximately an hour. When the gel was set, the top plate was removed, leaving
the gel on the back plate. This was placed on the Multiphor platform (Pharmacia LKP
2117 Multiphor Electrophoresis Unit), using a little distilled water in order to create
hydrostatic tension. The top and bottom areas of the gel were then covered with strips
of chromatography paper that had been wet with Tris Borate buffer. The electrode
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plate was then placed on the gel, ensuring that the electrodes were in direct contact
with the chromatography paper.
One microlitre of Multiphor loading dye (Appendix F) was added to ~ 5111peR
product. Each sample was then denatured at 95°e for 3 minutes and then placed on
ice. The samples were then loaded onto the gel and resolved at 355V for 90 minutes at
9°e. The gel was subsequently silver stained (Appendix G).
4.2.4.2 Direct Automated Sequencing
4.2.4.2.1 DNA Purification
A selection of samples was also analysed by direct sequencing. peR products were
purified using the Wizard® peR Preps DNA Purification System (Promega, USA).
Briefly, the 30111peR product was aliquoted into an eppendorftube and 100111Direct
peR Purification buffer was added to the tube. The tube was vortexed briefly. A
minicolumn was prepared for each sample with a Syringe Barrel attached and inserted
into the Vacuum Manifold. A lml resin aliquot was added, followed by the
ResinlDNA mix. A vacuum was applied to release the liquid. Thereafter, 2ml of 80%
isopropanol was added and the vacuum was again applied. The minicolumns were
then transferred to a 1.5ml Eppendorf tube and centrifuged at 10,000rpm for 2
minutes. The minicolumn was then transferred to a clean 1.5ml Eppendorf tube and
30111Nuclease-free water (preheated at 65°e) was added. After 1 minute the tube was
spun for 20 seconds, to elute the DNA.
An alternative method that was used for purifying DNA for sequencing is described
below.
Following successful amplification of the individual TACR3 exons, amplicons were
purified using the QIAquick® Gel Extraction Kit (Qiagen, USA). Briefly, the 20Il} of
each amplicon was resolved on a 1% agarose gel. Each band was then cut from the
gel and placed in a 1.5ml Eppendorf tube. The labelled tubes had been weighed
32
Stellenbosch University http://scholar.sun.ac.za
previously and were weighed again, following the addition of the gel slice. For each 1
volume of gel, 3 volumes of buffer QG was added. The tubes were then placed on a
heating block at 50°C for 10min. This process enabled the gel slice to dissolve and
free the DNA. After this incubation period, 100f.!1of isopropanol was added to each
tube and this was allowed to stand for 5 minutes. The solution was then transferred to
a prepared column that was placed in a collection tube and this was centrifuged for 1
minute at 13000rpm. The contents of the collection tube was discarded and another
500f.!1of the QG buffer was added to each tube. This was allowed to stand for 2
minutes and again centrifuged for 1 minute. Thereafter, 750f.!1PE buffer was added to
each sample and incubated for 5 minutes and then centrifuged for 1 minute. The
contents of the collection tubes were discarded and the columns were again
centrifuged for 1 minute. Finally, 30f.!1SABAX distilled water was added to each
column which was then placed in a fresh eppendorf tube, allowed to stand for 2
minutes and then spun for 1 minute to collect the DNA.
4.2.4.2.2 Sequencing Reaction
Following the DNA purification, the samples were resolved on an agarose gel to
confirm the presence of the pure product. Successful purifications were then subjected
to the sequencing reaction using the Big Dye® Terminator v.3.1 Cycle Sequencing
kit (Applied Biosystems, Foster City, CA).
Each reaction was carried out in a total volume of 20f.!1.This reaction mix was made
up of: ~3ng DNA, 4pmol either forward or reverse primer (Inqaba Biotec, RSA), 2f.!1
Terminator buffer, 1.0f.!1Big Dye® Terminator. These samples were subjected to
thermal cycling (Touchdown Hybaid Automated Thermal Cycler) at 96°C for 5
minutes, followed by 25 cycles of denaturation at 96T for 30 seconds and annealing
at 50DC for 15 seconds, followed by an extension at 60°C for 4 minutes.
The eentrisep Sephadex columns were then prepared. These columns were made with
6.25% Sephadex. Following preparation of the columns, 900f-l1Sephadex was added
to each column and this was allowed to 'set' for about an hour. Thereafter, the
columns were spun to allow any excess water to drain. A 20f-l1sequencing reaction
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was then transferred to each column. Special precaution was taken not to disturb the
column, which may lead to undesirable sequencing results.
These eentrisep columns trap the terminator and thus allowed for the desired sequence
to be eluted. The eluted products were then run on a ABI 3100 Automated DNA
Sequencer (Applied Biosystems, Foster City, CA).
The sequence data were analysed using BioEdit Sequence Alignment Editor. Bioedit
was also used to perform multiple alignments of sequenced products and to examine
sequence variants for restriction enzyme sites.
4.2.4.3 Restriction enzyme analysis
The MspI restriction digest was prepared in a total volume of 20.01l1 comprising
10.01l1 PCR product, 2.01l1 lOx Buffer B and 0.51l1 of IOU MspI (Promega, USA)
enzyme. These digestion samples were then incubated overnight in a waterbath at
37°C.
Following overnight incubation, these samples were mixed with loading dye and
resolved on a polyacrylamide gel (Appendix G), for 1 hour at 120Volts.
4.2.4.4 Statistical Analysis
All data were entered into an Access Microsoft database and analysed using
Statistica® or EPI info® for Windows. Discrete data were compared by calculation of
the relative risk and 95% confidence intervals or with the Fischer exact test where the
expected values of any cell in a two by two table was less than five. Allele
frequencies were determined by allele counting. Continuous data were compared with
Student's t-test for data with a normal distribution and the Mann-Whitney-U test
where there was not a normal distribution. A p-value of <0.05 was regarded as
statistically significant where appropriate.
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Chapter 5
Results
5.1 Patient Resource
Demographic and clinical data collected from participants are summarised in Table II.
Control Abruptio p-value Pre- p-value
(n=20) placentae a vsb eclampsia a vs c
a (n=10) (n=20)
b c
Homocysteine 6.57 12.69 0.02 8.25 < 0.05
(umol/t) (2-13.45) (4.28-37.3) (5.5-19)
Age (y) 31.90 24.4 < 0.05 22 < 0.05
(20-44) (18-32) (17-29)
Gravidity (n) 4.0 2.0 < 0.05 1 < 0.05
(2-5) (1-4)
Parity (n) 3.0 1.0 < 0.05 0 <0.05
(1-4) (0-3)
Diastolic 75.56 90.0 < 0.05 103.6 <0.05
bp(mmHg) (60-89) (60-120)
Gestational 40.0 34.0 < 0.05 27.5 <0.05
age (weeks) (37-41) (28-37)
Weight of 3567 1903 <0.05 803 < 0.05
baby (g) (2769- (916-2668)
4202)
Ranges are shown III parenthesis,
P values of < 0.05 are regarded as statistically significant.
Table II: Demographic characteristics of study patients
Table II demonstrated that the median age and gravidity was higher in the control
group, as is expected in a control group chosen specifically for multigravidity without
any previous hypertensive conditions. Homocysteine levels were significantly raised
in the pre-eclampsia patients and in those pregnancies further complicated by abruptio
placentae. The diastolic blood pressure was significantly raised in both patient groups,
specifically more in the pre-eclamptic patients. In the control group the babies were
born at term (40 weeks gestation), whereas the babies of pregnancies complicated by
abruptio placentae and pre-eclampsia patients had a mean gestational age of 34 weeks
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and 27.5 weeks, respectively. The control group had a median birth weight of 3567g,
compared to 1903g and 803g in the patients with pregnancies complicated by abruptio
placentae and pre-eclampsia patients, respectively.
5.2 Candidate gene screening
Numerous gene variants had previously been typed in the patient cohort as part of the
GAP project (Appendix H). It is important to consider these gene typings in all
analyses since there is likely to be a cumulative or interactive relationship between
gene variants underlying pre-eclampsia.
The results of this initial gene screening are outside the immediate scope of this thesis
but will be considered together with the TAC3 and TACR3 data as part of the GAP
study.
5.3 Genetic Analysis of Neurokinin B
5.3.1 Gene Annotation of the TAC3 and TACR3 genes
The TAC3 and TACR3 genes had apparently not been examined in relation to any
disease-state before. In order to ascertain the genomic distribution of the genes, full
sequence annotations were carried out using data available at the NCBI locus link
(http://www.ncbi.nlm.nih.govQ. Edited versions of the TAC3 And TACR3 genes
annotations are given in Appendices E and F, respectively. Full annotations are
available (GeneID: 6866 and 6870, respectively).
In order to fully examine the TAC3 and TACR3 genes by PCR, a complete set of
primers had to be designed. Exons larger than 350bps were covered by two or more
overlapping fragments. All primers were placed at least -60bps into the introns, so
that splice variants would not be overlooked in the screening. To minimise the level
of variation in PCR conditions, the parameters in the Primer3 program
(http://frado.wi.mit.edulcgi-binlprimer3/primer3 www.cgi) were set to standardise
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the following variables: primer length 18-21bps, GC content 50% ± 2%, and melting
temperature of 55°C ± 3°C. This yielded a set of PCR reactions that were all
optimised within 5°C of each other (Table III).
Name Exon Prod Tm Ta PrimerSequence(5'- 3')
Size Size (C) (C)
(bp) (bp)
TAC3-1 117 315 58 52 F-TGGGATTGGTGACTCTCAG
56 R-GAATAAAGCAGATGGCAGC
TAC3-2 119 297 60 55 F- AAGCCAAGCTGCTGGTAATG
60 R-GACAGCTGTAGTGAGGAAAC
TAC3-3 94 341 62 57 F-AGCACCTACTTCTCGTCCAG
66 R-CCTTTCAGATGGGAGAGAGATG
TAC3-4 30 282 60 55 F-TCTGAAGATAAGAGGCCTGG
60 R-CAAACAATATGCCAGCTCCC
TAC3-5 54 290 60 55 F-CTGTGAGGAGTCATGCTTTG
60 R-GAGGGAAAGACAGGACCTTT
TAC3-6 75 265 60 55 F-TTGAACACTGCCCGTCATAG
60 R-CCTCCCATGCTACAGGTATT
TAC3-7 287 420 64 55 F-AGGATATAAGATGTGATTTCAGTG
60 R-CTCCTCCAGCTACATGGTAA
TACR3-1a 691 354 60 55 F - ATTCTTTCTGCCTGCCAGAG
60 R-AGCCACCCAGTCTCAACTG
TACR3-1b 691 354 68 59 F-TGAACCTGACCGCCTCGCTA
64 R-ACGTGTTGAAGGCGGCCATG
TACR3-1c 691 351 60 53 F-TACTTCCTTGTGAACCTGGC
58 R-CACTCGAGGGCTACAAATG
TACR3-2 190 342 66 61 F-CCTTTGAAATACCTTTGAAACTCC
66 R-GTTGCTCCTAATCTGTAGTTTCC
TACR3-3 153 307 60 55 F-AAGCTGAGCCAATTCAGTCC
64 R-TTAACATGCCATGACTAGATTGC
TACR3-4 199 345 64 59 F-ATTGGCAGAAAAGCATGATTTGC
64 R-ATTGTATGTTTCCAGTGAAGGTG
TACR3-5a 529 335 62 55 F-GGTAGAATTTTCTGTGGCAGC
60 R-GCAGATTTGGAATTCCTGCG
TACR3-5b 529 384 60 55 F-ACCCAAGTTTCAATGGCTGC
60 R-CGAGTTTACAAGTATTTTCCTGAC
Table III: Summary of primer details and product sizes.
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5.3.2 peR Amplification
The peR amplification of each amplicon was optimised before the patients' DNA
samples were used. Figure VII represents the optimised peR amplifications of the
individual amplicons 1-7 of the TAC3 gene.
bp L 1 2 3 4 5 6 7
'-500bp
.-400bp
'-300bp
Figure VII: Photograph of TAC3 gene amplicons (exons 1-7) and Generuler™
100bp DNA Ladder (L) resolved on a 1.5% agarose gel. Lane 1 = 100bp DNA
ladder; lane 2 = amplicon 1 (315 bp); lane 3 = amplicon 2 (297 bp); lane 4 =
amplicon 3 (341 bp); lane 5 = amplicon 4 (282 bp); lane 6 = amplicon 5 (290 bp);
lane 7 = amplicon 6 (265 bp); lane 8 = amplicon 7 (420 bp).
Figure VIII demonstrates the amplification products obtained for amplicons 1a-5b of
the TACR3 gene. Exons 1 and 5 were each split into three and two amplicons,
respectively, to facilitate SSeP/heteroduplex analysis.
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L la lb le 2 3 4 Sa Sb
1031bp
500bp
400bp
300bp
Figure VIII: Photograph of TACR3 gene amplicons and Generuler™ 100bp
DNA Ladder (L) resolved on a 1.5% agarose gel. Lane 1 = 100bp DNA ladder;
Lane 2 = amplicon la (354 bp); Lane 3 = amplicon 1b (354 bp); Lane 4 =
amplicon Ic (351 bp); Lane 5 = amplicon 2 (342 bp); Lane 6 = amplicon 3 (307
bp); Lane 7 = amplicon 4 (345 bp); Lane 8 = amplicon 5a (335 bp); Lane 9 =
amplicon 5b (384 bp).
5.3.3 Mutation screening
5.3.3.1 Multiphor SSCPIHA
Multiphor SSeP/heteroduplex mutation screening was performed on aliquots of the
successfully amplified peR products. Each peR product had been diluted 1:5 in
loading dye. The sample was then heat denatured and a volume of ~3ulloaded onto
the horizontal gel.
The gels were run at a temperature of 9T on a standard matrix. No conformational
variants were detected in the ssep or heteroduplex components of this sytem (Figure
IX).
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1 2 43 5 6 7 8
Figure IX: Photograph of a standard Multiphor/SSCP gel of TACR3, amplicon
Sa. No conformational variants were detected.
Since no variants were discerned with the standard conditions, a sub-set of samples
was selected for automated sequencing, as a direct mutation detection method.
Concurrent with this, alterations were introduced to the Multiphor protocol. These
included the addition of Piperazine to the gel matrix and a temperature adjustment to
12°C. Subsequently, two conformational profiles could be discerned in products
representing TACR3 exon 5b. Lanes 1, 2, 5 and 7 and lanes 3,4, 6 and 8 in Figure X
represent the two "forms", respectively.
1 2 3 4 5 6 7 8
Figure X: Photograph of Piperazine Multiphor/SSCP gel run at Irc .
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5.3.3.2 Direct Automated Sequencing
Due to the initial lack of any variants being identified usmg the standard
Multiphor/SSCP analysis, it was decided to use automated sequencing as a
confirmatory technique. Because of the relative expense in using this technique, only
a subset of samples was selected.
A subset of twenty patients was selected and the TAC3 and TACR3 genes were
sequenced. Ten of these patients were from the primigravidae group with onset of pre-
eclampsia before 34 weeks gestation. The other ten patients had pregnancies
complicated by abruptio placentae with or without the HELLP syndrome. TAC3
amplicons representing the complete gene in 20 individuals were subsequently
column-purified using the Wizard® PCR Preps DNA Purification System (Promega,
USA) or QIAquick® Gel Extraction Kit (Qiagen) and sequenced.
Three variants in the TAC3 and two variants in the TACR3 genes were identified,
respectively, by sequence alignment using the BioEdit program and visual inspection
of each chromatogram.
The individual sequence variants were identified at the following positions in the
TAC3 gene:
(i) 5'UTR variant (-25 c-t);
(ii) Intronic variant IVS3-53 (t-g);
(iii) 3' UTR variant TAC3 exon 7 (479, t-c).
The individual sequence variants identified in the TACR3 gene are as follows:
(i) Exon 3 variant (nt 857, a-t; K286M);
(ii) 3' UTR variant, amplicon 5b (nt 1471, t-c).
The variants are discussed individually in further detail.
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5.3.3.2.1 TAC3 gene variants
(i) 5'UTR variant (-25 c-t)
At position -25 relative to the ATG start site, a transition (c-t) was identified (Figure
XI) in 6 of20 patients (allele frequency 8/40 alleles = 0.20).
A G c c c
180
C T G G c A C A
Figure XI: Representation of chromatogram indicating -25( c-t) transition in the
exon 1 containing amplicon. This individual is homozygous for the mutant Tallele
(position arrowed).
Four of the patients presented with pre-eclampsia, of whom one also had a pregnancy
complicated by abruptio placentae. The remaining two patients had presented with
only abruptio placentae.
Patient 4, a 32 year old G2P1 presented at 29 weeks of uncomplicated pregnancy with
an intra-uterine death due to 100% abruptio placentae. She was subsequently
diagnosed with hypertension but no proteinuria. The birth weight was 1426 grams.
Patient 5, a 27 year-old G3P2, presented at 37 weeks of uncomplicated pregnancy
with an intra-uterine death due to 100% abruptio placentae. There was no underlying
pre-eclampsia, but the baby only weighed 2050 grams. Patient 10, a 20 year old
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primigravida, presented at 34 weeks of pregnancy complicated by pre-eclampsia with
an intra-uterine death due to a 100% abruptio placentae. The birth weight was 1250
grams, far below the io" centile for this gestation. Interestingly, this patient also had
another variant, an intronic variant IVS3-53 (g-t) (see below).
Patients Il, 15 and 20 were all primigravidae with pregnancies complicated by early
onset pre-eclampsia. Patient Il presented at 24 weeks gestation with severe pre-
eclampsia and reversed end-diastolic flow in the umbilical artery as measured with
Doppler. The pregnancy was terminated due to the severity of maternal disease. The
fetus weighed 500 grams. Patient 15 presented at 22 weeks with severe eclampsia and
the pregnancy was terminated due to the maternal condition. The infant weighed 726
grams and did not survive. Patient 20 presented at 32 weeks with severe pre-
eclampsia and an infant of 1956 grams was delivered after induction oflabour.
Patients 4 (abruptio placentae only) and Il (pre-eclampsia only) were homozygous
for the -25 c-t variant, while the remaining patients were heterozygotes.
This variant was subsequently confirmed in the SNP database (accession number
2291855). An allele frequency of 0.10 was reported (in 48 alleles) in an unspecified
population.
Application of the electronic SMS (Bioedit) utility, provided additional information
on alternative methods of detecting the variant form. The mutant t allele abolishes one
of the two MspI and Hpall restriction enzyme sites (ccIgg). For the purpose of this
study, the restriction enzyme, MspI was used.
TheMspI recognition site is: CTCG G
G GC"_C
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cc CT TT
133 bp
107 bp
75 bp
315 bp
182 bp
+
Figure XII: Schematic drawing ofMspI restriction enzyme map
This restriction site is useful in increasing the throughput of variants rather than the
expense of sequencing.
1 2 73 6 8 9 104 5
Figure XIII: Photograph of MspI restriction enzyme digestion. Lanes 1 and 4
represent homozygote mutants (tt), lanes 2, 3, 5 and 6 represent heterozygotes
(ct) and lanes 7, 8 and 9 represent homozygote wild types (cc). Lane 10
represents an uncut peR product.
315bp
182bp
133bp
107bp
75bp
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The frequency of this promoter variant in 42 control subjects (population-matched)
was therefore determined by PCR amplification followed by restriction enzyme
analysis (Figure III). There were 12 heterozygotes in this control population of 42, but
no homozygous individual. A mutant t-allele frequency ofO.14 was determined.
The allele frequency of the mutant t allele in diseased and controls in this population
compared statistically as follows: Odds Ratio (OR) of 1.5, with a 95% Confidence
Interval (Cl) of 0.5-4.44. The p value was non significant at 0.41. When comparing
the genotype frequency, the same results were obtained when heterozygotes and
homozygotes were combined (OR 1.07, 95% Cl 0.28-3.97;p value 0.9).
In the companson of homozygous patients with combined wild-type and
heterozygotes, a Relative Risk (RR) of 3.33 (ranging between 2.26 and 4.91) was
obtained with a significant p value of 0.037 and implies that variant homozygosity
status impacts negatively on health.
(ii) Intronic variant IVS3-53 (t-g)
Three samples each demonstrated a t-g change at position IVS3-53. An allele
frequency of 0.075 was determined. This site is not within the conventional splicing
branch site and most likely reflects a standard SNP and did therefore not warrant
further investigation at the time. No restriction enzyme site is recognised within this
particular region.
c G c T c N c A T
70
C
Figure XIV: Representation of chromatogram indicating the intronic
variant IVS3-53 (t-g). Heterozygous status is shown (see arrow).
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Patient 9, a 22 year old G2P1, presented at 33 weeks gestation with the clinical
diagnosis of pre-eclampsia and abruptio placentae and a live infant was delivered,
weighing 2050 grams. Patient 10 was discussed earlier. Patient 19 was also a
primigravid patient with early-onset, severe pre-eclampsia at 33 weeks. She delivered
an infant of 1778 grams.
One of these patients was from the early onset, severe pre-eclampsia cohort while the
remaining two patients presented with pre-eclampsia and abruptio placentae. One
patient with the IVS3-53 variant was also heterozygous for the -25c-t promoter
variant. Her clinical phenotype was described above.
The exon 3 amp licon was subsequently amplified (by PCR) in 25 controls and
resolved on multiphor SSCP gels. No variants could be detected (50 alleles).
No restriction site was created or abolished by the IVS3-53T variant. However, the
position of this variant requires some discussion due to its proximity to the intron-
exon boundaries. Although it appears to be close to the branch site, it cannot be
excluded since it may playa role in splicing. Therefore, further characterisation of
this variant is required by functional studies.
(iii) 3' UTR variant TAC3 exon 7 (nt 479, t-c)
A single variant could be discerned in the fragment corresponding to the untranslated
exon 7 amplicon. A transition (t-c) was identified at position 479 relative to the ATG
start site in patient 13. An allele frequency ofO.025 (1 C allele in 40) was determined.
No restriction enzyme site was recognised within this particular region.
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A A G c A c N A
220
G A
Figure XV: Representation of chromatogram of 3' UTR variant. Reverse
complement. A heterozygous individual for the mutant t-e transition is shown (see
arrow).
This patient 13 presented at 26 weeks with severe pre-eclampsia and she was admitted
for conservative management. The infant was delivered by Caesarean section at 27
weeks due to fetal distress and weighed 892 grams.
Due to its location within the 3'UTR (regulatory) region of the gene, functional
studies should clarify the role of this variant.
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5.3.3.2.2 TACR3 Gene variants
(i) Exon 3 variant (nt 857, a-g) / K286M
T G A
40
T A c y T G T C A C
FigureXVI: Representation of chromatogram indicating the exon 3 variant. A
heterozygous status (a-g) is shown. Chromatogram reverse complement.
At nucleotide 857 relative the ATG start site (exon 3), a transition (a-g) was identified
in one individual (patient 17) at an allele frequency ofO.025. This patient was a 19
year old primigravida with severe pre-eclampsia. She delivered an infant of 874
grams at 30 weeks gestation.
This variant was subsequently identified III 2 of 21 control individuals (by
Multiphor/SSCP gel electrophoresis).
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(ii) 3'UTR variant, amplicon 5b (nt 1471, t-e)
A T T T
140
A Y c A G T c c
Figure XVII: Representation of chromatogram indicating 3'UTR variant.
Heterozygous individual shown (see arrow).
At nt 1471 of amplicon 5b, encompassing exon 5 in the 3'UTR region, a substitution
(t-e) was identified in 13 of 18 patients. [The reference sequence quoted on NCB!
most likely reflects the mutant and not wildtype allele since in our study, we only
identified one CC genotype].
There were four individuals in our group that represent the wildtype (tt) and the
remaining 13 were heterozygotes (te). This represents an allele frequency of 0.58 for
the t allele and 0.42 for the c allele. All of these patients had severe pre-eclampsia,
complicated in five cases by abruptio placentae. Eleven of the thirteen heterozygotes
were primigravidae with severe early onset pre-eclampsia.
The clinical statistics of the heterozygous patients identified with this variant were as
follows: The mean age of the patients was 21.14 (range 17-27), the median gravidity
was 2 (range 1-3) with a parity median of 1 (range 0-2). The mean gestational age was
31.4 weeks (range 28-37 weeks) and the mean infant mass was 1470 g (range 500-
2668 g).
This variant was subsequently confirmed on the SNP database (accession number
2765).
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In the analysis of control samples, the variant was identified at very similar
frequencies.
Table IV is a summary table of the TAC3 and TACR3 genes variants.
In the analysis of the sequencing data, several repeat motifs, eg. 'CCTCTCCTCCT'
motif in amplicon lb of the TACR3 gene, were noted which may be polymorphic.
These regions will be further characterised since identification of micro satellite
markers may be useful for future association studies.
50
Stellenbosch University http://scholar.sun.ac.za
TAC3 TACR3
Patient 5'UTR (-25 c-t) IVS3-53 (t-g) 3'UTR (479, t- K286M / 857 a- 3'UTR (1471, Features I
c) g t-e)
1 +/- G2P I; pre-eclampsia; abruptio placentae
2
3
4 +/+ G2P I; abruptio placentae
5 +/- +/- G3P2; abruptio placentae
6 ,
7 +/- GIPO; abruptio placentae
8 +/- GIPO; abruptio placentae
9 +/- +/+ G2P I; pre-eclampsia; abruptio placentae
10 +/- +/- +/- G IPO; pre-eclampsia; abruptio placentae
11 +/+ +/- GIPO; early onset severe pre-eclampsia
12 +/- G IPO; early onset severe pre-eclampsia
13 +/- +/- GIPO; early onset severe pre-eclampsia
14 +/- GIPO; early onset severe pre-eclampsia
15 +/- +/- GIPO; early onset severe pre-eclampsia
16 +/- G IPO; early onset severe pre-eclampsia
17 +/- +/- G IPO; early onset severe pre-eclampsia
18
19 +/- G IPO; early onset severe pre-eclampsia
20 +/- +/- G IPO; early onset severe pre-eclampsia
V1.....
Table IV: Summary table of TAC3 and TACR3 genes variants and clinical phenotypes
Key: -/- = homozygous wild-type, no mutant allele;
+/- = heterozygote status;
+/+ = homozygous mutant.
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Chapter 6
Discussion and Future Prospects
The TAC3 and TACR3 genes were found to harbour several sequence variants. These
variants were distributed across the genes, encompassing the 5'UTR, exonic, intronic
and 3'UTRs. The majority of these variants appear to be novel, with only the TAC3 5'
UTR -25(c-t) and TACR3 1471(t-c) variants documented in the SNP database. Data
on the remaining variants will be deposited in the SNP and relevant mutation
databases and so contribute to the growing knowledge of the human genome.
Each of the variants identified in this study represents a single base pair substitution.
No deletions, insertions or obvious rearrangements were identified. Of the five
variants, four are transitional changes: TAC3 -25 c-t, 3' UTR nucleotide 479 t -c and
TACR3 exon 3 nucleotide 857 a-g and amplicon 5b nucleotide 1471 t-e. The only
transversion change was the TAC3 IVS3-53 (t-g).
The variants were detected by automated sequencmg, which although costly, is
regarded as one of the most accurate mutation detection methods. The Multiphor
SSCP/HA did initially not reveal any variants at a constant running temperature of
9°C, and on a standard gel matrix. Since most SSCP protocols recommend adjusting
the running conditions, this was done concurrently with direct automated sequencing
of selected samples.
Conformational variants were then identified by Multiphor analysis, after piperizine
had been added to 'tighten' the gel matrix and the running temperature altered to
1rC. Amplicons of close to 400 bp could then be distinguished with the adjusted
protocol and the two variants identified in the TACR3 gene by automated sequencing,
could be confirmed by the presence of SSCP conformational variation. The sequence
variation was not reflected in the heteroduplex bands on the gels.
Selecting a subgroup of patients to be processed by automated sequencing proved to
be a difficult task. It was decided to select groups that would include patients with (i)
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only early, onset severe pre-eclampsia, (ii) with only abruptio placentae and (iii) those
with a combination of both, since it is believed that these conditions may share a
common pathological pathway. So, although the patient groups analysed in this study
were originally small (due to expense involved in automated sequencing), these
patient groups can now be extended to further characterise the positively identified
variants.
Only one variant was identified in the 5' untranslated region of the genes. The c-t
change at position -25 relative to the ATG start codon of the TAC3 gene, is
suggestive of a promoter-region variant, with classic Eukaryotic regulatory motifs
such as TATA boxes often residing at such locations. It is believed that the 5'UTR
- 30 nt region immediately upstream from the start codon of most genes is highly
conserved and therefore may play a critical role during transcription, and
consequently, translation (Shabalina et al., 2004). Detailed bioinformatie searches are
currently underway to characterise the 5'UTR and specifically, the complete promoter
region of the TAC3 gene. Variation within a promoter, is expected to impact
significantly on the expression of that gene, with or without sequence variation
elsewhere in the gene (or the modulating receptor). The conservation "profile" of the
gene will also be analysed phylogenetically.
However, since the frequency of this variant has already been established at 0.10 in a
control population (SNP database), matched closely with our own control panel
(0.14), it would seem unlikely that variation at this site is strongly detrimental. Do the
observations of (i) an allele frequency of 0.2 in the patient cohort and (ii)
homozygosity for the variant restricted to patients, suggest otherwise? An answer is
not immediately clear since one homozygous patient (patient 4) presented clinically
with a pregnancy complicated by abruptio placentae and another (patient 11) with
pregnancy complicated by early onset severe pre-eclampsia, while two of the
heterozygotes (patients 15 and 20) presented with early onset severe pre-eclampsia,
one heterozygote (patient 5) with pregnancy complicated by abruptio placentae and
the remaining one (patient 10) with early onset severe pre-eclampsia further
complicated with abruptio placentae. The difference in genotype frequency between
patients and controls (0.20 vs 0.14) may indicate that this variant impacts slightly on
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susceptibility to "placental vasculopathy". lts effect may also be context-dependent in
that expression of the variant allele may depend on the presence or absence of specific
sequence variants at other loci (possibly like the TACR3).
An intronic variant was identified in the exon 4-encompassing amplicon of the TAC3
gene and designated IVS3-53 (t-g). This novel variant was identified in the
heterozygous state in three individuals. Although this variant appears not to be at a
critical position w.r.t. the intron/exon junction (it is located 53bp before exon 4), it
may impact on splicing and possibly generate alternative splicing forms of the TAC3
transcript. This possibility can be addressed by functional analysis where this mutant
allele is cloned into a suitable vector and its splicing potential assessed (Zaahl et al.,
2004).
Two variants were located in the 3'UTR of the individual genes, viz., TAC3 exon 7
and TACR3 amplicon 5b. Both these variants were single base substitutions in single
individuals. Sequence variation in the 3'UTR is thought to influence transcript
stability (Kuersten et al., 2003), therefore further characterisation of these variants are
required.
The only exonic mutation identified in the study (a-t change at nucleotide position
837) resulted in the substitution of Lysine (K) for a Methionine (M) residue in exon 3
(K286M) of the TACR3 gene in a single patient with severe pre-eclampsia. Lysine is a
positively charged, basic hydrophilic amino acid and Methionine is a non-polar
hydrophobic molecule. The location of this amino acid substitution within the NKB
receptor protein is critical since it may affect the structure/conformation (and
consequently function).
When further analysing the patients with the TAC3 5'UTR -25 variant, it was
interesting to note that the two homozygotes for this variant (patients 4 and 11), had a
very similar genetic profile with regards to 5 candidate genes screened (Appendix H).
The only difference in their genetic profiles was that patient 4 was heterozygous for
both the MTHFR c677t and the a1298c variants, while patient 11 was only
heterozygous for the a1298c variant. This may be significant in the cummulative
effect of gene variants.
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Five patients (patients 5, 10, 11, 15, 20) were identified as combined heterozygotes
for the TAC3 5' UTR -25 variant and the TACR3, 3'UTR amplicon 5b variant. Further
analysis of this combination would be significant since the 5'UTR and 3 'UTR are
considered to be modulators and thereby contribute to the regulation of transcription
(Sonenberg 1994 and Shabalina et aI., 2004). These patients did not show any
obvious differences in their gene profile of the candidate genes (Appendix H) . Patient
10 was identified with the TAC3 IVS3-53 variant as well, so this individuals sample
should definitely be included in functional studies. This patient presented with early
onset severe pre-eclampsia further complicated by abruptio placentae, therefore
heterozygosity for the abovementioned variants may be a susceptibility status for
these conditions.
One patient (patient 13) with early onset severe pre-eclampsia was a combined
heterozygote for the TAC3 3'UTR exon 7 and the TACR3 amplicon 5b variants, both
confined to the 3' untranslated regions. Another primigravida patient (patient 17)
presenting with severe pre-eclampsia was a combined heterozygote for the TACR3
exon 3 and 3'UTR amplicon 5b variants. Interestingly, both these patients were
homozygous wildtype for 5 other gene variants screened (Appendix H), except that
they were homozygous mutant carriers for the AGT variant. These samples would be
useful for the functional studies.
This leaves the question whether these variants could alter "normal" NKB function
and so predispose an individual to placental vasculopathy like pre-eclampsia and
abruptio placentae? Page and Lowry (2000) first proposed a potential role for NKB in
the pathogenesis of pre-eclampsia: when an ischaemie placenta develops due to the
defective trophoblastic invasion of the spiral arteries, the placenta starts to secrete
increased levels of NKB. This then stimulates the NK3 receptors (the preferred
receptor of NKB), which in tum leads to the constriction and contraction of the
mesenteric and hepatic portal veins. This ultimately results in an increase in the blood
pressure and potential damage to the liver and kidneys, in order to satisfy the greater
demand for blood to the uterus and placenta. This mechanism of action by NKB
would also explain the low or undetectable levels of NKB in normotensive
pregnancies (D' Anna et al., 2002 and Page et al., 2000).
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We speculate that when the TAC3 and TACR3 genes are not functioning "normally"
due to variants in the genes, then the NKB levels may be increased/decreased to
compensate for this lack of function. It may be that the affinity of NKB for its
receptor becomes diminished, or the receptor itself looses specificity. This question
could only be answered following functional studies.
Since patients have been identified with variants in the both the TAC3 and TACR3
genes, it may be essential to further elucidate the interaction between the two
genes/gene products. Neurokinin B seems to be the only tachykinin produced by the
placenta that interacts with the peripheral tachykinin receptors (Page and Bell, 2002).
It will be interesting to watch future micro array studies that may identify any other
gene/gene products that may interact with NKB.
Neurokinin B has been found to be expressed in higher concentrations in older rats
(Cintado et al., 2001) and it is further believed that NKB expression may be
hormonally controlled (Page et al., 2001). Oestrogen response elements have been
identified in the 5'UTR of the TAC3 gene (Page et al., 2001) and therefore future
functional studies (like Luciferase-reporter transfection studies) should include
environmental variables such as hypoxic conditions (mimicking the pre-eclamptic
placenta) and possibly also fluctuating oestrogen concentrations in the media to gauge
the influence of these stimuli on the expression of the particular gene construct.
When comparing the mutation detection methods, it becomes apparent that even
though variants were not identifiable on the Multiphor system, they were identified by
direct sequencing. Although direct sequencing has been described as the 'gold
standard' (Kirstensen et al., 2001) in mutation detection methods due to its high
sensitivity, it is extremely costly for use in routine screening. Since the Multiphor
system yielded some variants when the gel matrix and environmental factors were
adjusted, one has to include these variables when using this mutation detection system
in order to fully appreciate its significant advantages such as high throughput and cost
effectivity.
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Extensions of this project should include the following:
i) Extending the study cohort (patients and controls) by further characterising
the variants in the TAC3 and TACR3 genes that have been identified.
ii) Identifying alternative methods for detecting the variants that do not create
or abolish restriction enzyme recognition sites in larger control and patient
cohorts. Sequencing is generally too expensive for large-scale screening.
Alternative SSCPIHA protocols and systems should be evaluated.
iii) Functional studies of the variants. The 5' and 3' regions of the TAC3 and
TACR3 genes would be significant in this regard. Constructs with a variety
of alleles can be generated and these could be expressed in tissue culture in
classical transfection studies. A variety of environmental factors can be
introduced including hypoxia, oxidative stress, and fluctuating hormone
concentrations and the influence thereof measured on gene expression ..
iv) Individuals who were identified with more than one variant should be
followed up and family studies performed in order to track the
transmission patterns of the variants and evaluate NKB levels in the non-
pregnant state.
v) Variant combinations (like the TAC3 5'UTR -25 / TACR3 3'UTR) should
be investigated on a biochemical level, including receptor/ligand kinetic
studies.
In conclusion, the aims of the study have been met. These data have contributed to
knowledge of the Human Genome and have led to the documentation of novel
sequence variants, which may be associated with altered NKB levels. The link
between NKB and pre-eclampsia remains to be established, and requires further
investigation. Ultimately, it is hoped that studies such as this will facilitate the
development of a predictive test for pre-eclampsia, and lead to "tailored" treatment
for this life-threatening condition.
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STELLENBOSCH UNIVERSITY
FACULTY OF HEALTH SCIENCES
INFORMATION AND INFORMED CONSENT DOCUMENT FOR
DNA ANALYSIS AND STORAGE
TITLE OF THE RESEARCH PROJECT
REFERENCE NUMBER
PRINCIPAL INVESTIGATOR
Address:
DECLARATION BY OR ON BEHALF OF PARTICIPANT:
I, THE UNDERSIGNED, .. ..... (name)
[ID No .... ] the participant/tin my capacity as
. .. ] ct
of the participant [ID No
(address).
A. HEREBY CONFIRM AS FOllOWS:
1. I/'The participant was invited to participate in the above-mentioned research project of the Department of
, Faculty of Health Sciences, University of Stellenbosch.
2. The following aspects have been explained to me/'the participant
2.1 Aim: Worldwide new causes of certain diseases or conditions are continuously being discovered
by research on the cells and molecules of the body This project aims to
...... Additionally, this project
aims to collect genetic material (blood andlor tissue from surgical procedures) to analyse for certain
defects (mutations) and to store excess material for future research When a large group of
patients with similar diseases has been collected, meaningful research into the disease processes
may become possible.
2.2 Procedures: II'The participant will be requested to provide information about myl'his/'her
medical history. Depending on the underlying problem or disease, blood (1ami, about 2
teaspoonfuls) andlor tissue (obtained only when surgery for the disease is deemed essential, the
sample needed is 100mg, about the size of a match head) will be collected from me/*the
participant After myl'the participant's and my/'the participant's immediate family's written
informed consent has been obtained, blood (also 10m/) or a mouth wash sample may be requested
from my/'the participant's immediate family to investigate whether there is an underlying familial
(genetic) cause for this disease
2.3 Genetic considerations:
Jó- The blood or tissue may be used to create a cell line, which can grow indefinitely and can be
used to synthesize more of rny/'the participant's Dt'.jA al any time in the future;
Jó- The DNA may be stored for several years until the technology for meaningful analysis
becomes available,
,. The results of the analyses carried out on this material in the current study will be made
known to me/*the participant in accordance with the relevant protocol, if and when it
becomes available In addition, I/'the participant authorisets) the investigator(s) to make
the information available to .. (doctor's name), the doctor
involved in my/'the participants care, as wei! as to the following family members
(names),
);- The DNA will be maintained indefinitely, unless I/'the participant request(s) to have it
and/tor the stored clinical data destroyed by contacting the investigator conducting the
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8. I/*The participant have/*has received a copy of this document for my/*his/·her records.
9. The Research Subcommittee C/Ethics Committee, Faculty of Health Sciences, Stellenbosch University,
has approved recruitment and participation of individuals in this study on the basis of
• Guidelines on Ethics for Medical Research of the SA Medical Research Council;
• Declaration of Helsinki;
• International Guidelines. Council for International Organisations of Medical Sciences (CIOMS),
• Applicable RSA legislation
B. HEREBY CONSENT VOLUNTARILY TO PARTICIPATEI*ALLOW THE POTENTIAL PARTICIPANT TO
PARTICIPATE IN THIS STUDY:
Signed/·Confirmed at . on .. . 20 .
(date)(place)
Signature or right thumb print of Signature of witness
participant/*representative of participant
DECLARATION BY OR ON BEHALF OF INVESTIGATOR(S):
I, .. . (name) declare that
• I explained the information in this document to ... .... (name of the patient/·participant)
and/or his/her representative...... ..... (name of the representative);
• shel*he was encouraged and afforded adequate time to ask me any questions;
• this conversation was conducted in Alrikaansr'Enqlish/txhosar'Other and no
translator was used/'was translated into ..... (language) by
.... . (name)
Signed at .... on. ...20.
(place) (date)
Signature of investigator/representative of investigator
DECLARATION BY TRANSLATOR:
Signature of witness
"'Delete where not applicable .... . (name) confirm that I
o translated the contents of this document from English into. .. (language),
• explained the contents of this document to the participant/'the participant's representative;
II also translated the questions posed by
given by ...
(name) as well as the answers
(name), and
• conveyed a factually correct version of what was related to me
Signed at. on . .20.
(place) (date)
Signature of translator Signature of witness
IMPORTANT MESSAGE TO PARTICIPANTf*REPRESENTATIVE OF PARTICIPANT:
Dear participantr'representative of participant,
Thank you very much for your/'fhe participant's participation in this study. Should, at any time during the study,
.. an emergency arise as a result of the research, or
.. you
kindly
require
contact
any further information with regard to the
(name)
study,
at
. (telephone number/address).
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present study,
or the
(name) (telephone number)
Chairperson ol the Research Subcommittee C/Ethics Committee at
.. (telephone number) il the former cannot be located;
;,... The analyses in the current study are specific to the condition or disease mentioned above
and cannot determine the entire genetic make-up of an individual;
r Genetic analyses may not be successful in revealing additieaal information regarding some
families or some family members,
;_. Even under the best conditions, current technology of this type is not perfect and could lead
to unreliable results
2.4 Confidentiality: MyrThe participant's identity will be kept confidential throughout. Information
will not be associated with my/'the participant's name. The research staff will use only a coded
number, access will be limited to authorized scientists and any scientific publications, lectures or
reports resulting from the study will not identify merthe participant by name.
2.5 Voluntary participation: Participation is voluntary and lI·the participant may decline participation,
or withdraw from the study at any time without any loss of benefits to which I aml*the participant is
otherwise entitled. Future management at this or any other institution will not be compromised by
r"fl I<'':""'ll nr \,I.,,;thrlr:-tv;-:-,j
2.6 Risks: There are no more than minimal medical or psychological risks associated with this study:
;... I!*The participant may feel some pain associated with having blood withdrawn from a vein
and may experience discomfort, bruising and/or slight bleeding at the site;
» As some insurance companies may mistakenly assume that myl*the participant's
participation is an indication of a higher risk of a genetic disease which could hurt myl*the
participant's access to health or other insurance, no information about meJ*the participant or
myl*the participant's family will be shared with such companies as this investigation cannot
be regarded as formal genetic testing for the presence or absence of certain genes.
2.7 Benefits:
;... Although there may not be any direct benefits to mel*the participant by participating at this
stage, family members and future generations may benefit if the researchers succeed in
scientifically delineating certain disorders further. Thereby the rational approach to the
clinical diagnosis and therapy of its manifestations may be facilitated. The identification and
location of the genes involved in such disorders, could in the end lead to the development of
methods for prevention and to forms of new treatment aimed at curing or alleviating these
conditions;
;... In the unlikely event that the research may lead to the development of commercial
applications, lI'the participant or my/*the participant's heirs will not receive any
compensation, but profits will be reinvested into supporting the cause of further research
which may bring benefits to my/'the participant's family and to the community, such as
health screening, medical treatment, educational promotions, ete;
2.8 Permission for further studies: Before my/*the participant's material is used in further projects in
the future, the written approval of the Research Subcommittee C/Ethics Committee, Faculty of
Health Sciences, will be obtained
3. The information conveyed above was explained to me/'the participant by
(name) in
and I am/*the participant is fluent in this language!* wasAfri kaa ns!E ngIish/Xhosa/Other*
translated and explained by
(name)
4. II*The participant was afforded adequate time to pose any questions and all questions were answered to
my/*the participant's tuil satistaction
5. II'The participant was not pressurized to participate
6. II'The participant will not be paid tor participation, but reimbursement of travel costs will be considered (if
applicable).
7. II'The participant will not incur any additional costs through participation.
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Appendix C
Questionnaire
GENETIC ASPECTS OF PREECLAMPSIA:
3. GRAVIDITY:PARITY: MISCARRIAGES:ECTOPIC:
PREVIOUS
PREGNANCIES:
4. YEAR:
5. PARTNER: (NO)
6. G.A. COMPLICATIONS:
7. COMPLICA TIONS:(LIST)
8. METHOD DELIVERY:
9. BIRTH WEIGHT:
10. G.A.-DELIVERY:
11. OUTCOME: (LIST)
12. NICU: YES=1,NO=2
13. SMOKE: YES =1, NO =2
14. ALCOHOL: YES=1,NO=2
NAME:
HOSPITAL NO:
BIRTHDATE:
1. AGE:
2. RACE:
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CURRENT PREGNANCY:
15. VDRL: NEG =0, POSTREATED =1,NOT TREATED =2
16. BLOOD GROUP:
17. CERVICAL CYTOLOGY:NORMAL =1ABNORMAL =2
18. CERVICAL CULTURES:
NOT DONE =1,NEG=2, GONO =3, CHLAMYDIA =4, GBS =5, OTHER =6
19. URINE MCS: NEG =0, ASYMP.BACTURIA TREATED =1,NOT TREATED =2,
NOT DONE =3, UTI =4
20. SF GROWTH: <10th =1,NORMAL =2, >90th =3
21. PROTEINURIA: (GESTATION)
22. BP:(ADMISSION)
23. AMNIOCENTESIS FOR KARYOTYPING: YES =1.NO=2(GESTATION)
24. FETAL MOVEMENTS: NORMAL =1,DECREASED=2
25. ULTRASOUND: YES =1,NO =2
26. DOPPLER:N =1,>95TH =2, AEDV =3, REDF=4
27. G.A. WHEN COMPLICATIONS DEVELOPED:
28. COMPLICATIONS: _
29. SMOKE: YES =1,NO =2
30. ALCOHOL: YES =1,NO =2
31. MEDICATION AT ANY TIME DURING PREGNANCY: I_I
FOLATE =l,Fe =2, ASPIRIN =3, ANTIHYPERTENSIVES =4, PYRIDOXIN =5, OTHER =6
A T DELIVERY:
32. GESTATION:
33. BIRTH WEIGHT:
72
Stellenbosch University http://scholar.sun.ac.za
33A MALE =1,FEMALE =2
33B DELIVERY TYPE:
34. APGARSCORE:
35. OUTCOME: (LIST)
36. MORBIDITY:(LIST)
37. NICU: YES =1,NO =2
38. DAYS:
39. REASON:
40. SPECIAL INVESTIGA TIONS:
UREUM: I I
KREAT:
AST:
LDH:
WCC:
HB:
ALT: HKT:
GENERAL
INFORMA TIOM
ADDRESS:
BORN AND RAISED:
41. YOURSELF:
42. YOUR MOTHER:
43. YOUR FATHER:
44. CURRENTPARTNER:(FATHEROF YOUR CHILD)
45. YOUR PARTNERS MOTHER:
46. HAS SHE HAD TROMBOTIC EPISODES:
47. ANY COMPLICATIONS DURING YOUR PARTNER'S BIRTH: _
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48. PREVIOUS PARTNER(S) -CHILDHOOD AND PLACE OF BIRTH:
49. DO YOU HAVE SISTERS OR HALF SISTERS WHO HAVE THE FOLLOWING COMPLICATIOf\
PRETERM BIRTH =1, DEAD BABY =2, BLEEDING LATE IN PREGNANCY =3,HIGH BLOOD
PRESSURE =4
ADDRESS OF SISTER:
50. DID YOUR MOTHER HAVE ANY OF THE FOLLOWING:
PRETERM BIRTH =1, DEAD BABY =2, BLEEDING LATE IN PREGNANCY =3,HIGH BLOOD
PRESSURE =4, THROMBOSIS =5
74
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Appendix D
The GAP participants were subdivided into 9 groups (Groups A-H), consisting of at
least 50 patients.
(i) Group A: control group of patients with pregnancies uncomplicated by any
hypertensive condition in the index pregnancy or any previous pregnancy;
(ii) Group B: primigravidae patients with early onset severe pre-eclampsia;
(iii) Group C: primigravidae patients with late onset pre-eclampsia;
(iv) Group D: multigravidae patients with early onset severe pre-eclampsia;
(v) Group E: multigravidae patients with late onset pre-eclampsia;
(vi) Group F: primigravidae patients with pregnancy-induced hypertension
only;
(vii) Group G: multigravidae patients with pregnancy-induced hypertension
only;
(viii) Group H: pregnancies compli=ated by placental abruption and some with
the HELLP syndrome;
(ix) Group I: pregnancies complicated by IUGR.
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Appendix E
TAC3 Gene Annotation
Annotated sequence file:
LOCUS NT 029419
19-FEB-2004
10502 bp DNA linear CON
DEFINITION Homo sapiens chromosome 12 genomic contig.
ACCESSION NT_029419 REGION: complement(19545092 ..19555593)
VERSION NT 029419.10 GI:29803948
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 10502)
AUTHORS International Human Genome Sequencing Consortium.
TITLE The DNA sequence of Homo sapiens
JOURNAL Unpublished (2003)
FEATURES Location/Qualifiers
source 1..10502
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db xref="taxon:9606"
/chromosome="12"
ORIGIN
1 tggctcactg aaacctccgc cccctgggtt caagccattc tcctgcctta gcctcctgag
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61 tagctgggat tacaggggtg tgccaccacg cccagctaat ttttgtattt ttagtacaga
121 cagggtttca ccttgttggt caggctggtc tcaaattcct gaccttgtga tccacctgcc
181 tcggcctccc aaagtgctag gattacaggc gtgagccact gtgcccggcc tttttttttt
241 tttttttttt ttaggaagtt gtattttggg ctttttaact agcttgtttt ttaattagat
301 tattgccttt agggtggagc cctttaataa aaagggggaa gaaaacatag gttttagggc
361 ctcatattta aatgggtaaa gcaggcatag ctggaaggca gaatacagaa cccccctaat
421 caaggatctc atttttatat tgaatcctag gccccccaaa agagggaaat gtcatgggac
481 gagatgtgtg gcatttttat cgagtgcccc actgtaaaga tgctccccca aggctggcag
541 gcagcccagt geegattage ccactctgtg cttagtcttt tttttttttt tttttttgag
601 gtggagtctt gctctgttgc ccaggctgga gtgcaatggc gtgatctcgg ctcaatgcaa
661 tctctgtctc gtgggttcaa gcgattctcc tgcctcagcc tcccaagtag ctgagattac
721 aggeaceage cactatgctc agctaatttt ttgtattttt agtagagatg gggtttcaac
781 atgttggcca ggctggtctc gaacttctga ccccaagtga tccgcccgcc tcggcctccc
841 aaagtgctgg gattacaggc gtgagccacc atgcctggcg tgcttagcct atttttaatg
901 ggagtttcat cctcaatggt gagtgctttc attgtcttta ggtgccccag accatgtttt
961 taaaaattta aatgcacgaa gaaataagta gccctgtata gtagtaatac tttgttgtga
1021 ataactgtca taagtcatct ctaaaactgt attttttatc tagttattat atatgactag
1081 ctatatgtct agttttttaa ataatacaaa gtaatttatt tttggcatcc tcaaaaacca
1141 aagagattag gtaatgtagt gtagaagaga gcagagcttt agacctgaga agaatctgcc
1201 catgaetegt gaaactccac aacgaaagta ggagacccca aaaaaggggt gagtgtcatc
1261 ttttctgaat tttttttttt ttttagatgg agtcttgctc tgccaccagg ctggagtgca
1321 gtggtgcaat ctcggctcag cctcccgagt agetaggatt acaggcacgc gccaccatga
1381 ccagctaatt tttgtatttt tagtagagac agcgtttcac catgttggcc aggatggtct
1441 cg=atctcttg acctcgtgat ccgcccgcct cggcctccca aagtgctggg attacaagcg
(G/A)(dbSNP:695934)
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1501 tgagccactg cactcggccg gtcagataat ttttttggcc agtttttaca tagagtaatt
1561 ttaggtttta tggctggctt tggggcaaag gggttctggt ttttatagct ggtcttgggg
1621 gagaatggaa ccgagtgaca agaggacaag agagggtcag agaaaaactt ctgcttctga
1681 ggcggctatt gaggccttca ttttggagta ttgtcctcta agccccagca gtgtcaaact
1741 gtacacaaac catacacagc agccagctcg ggtgctgtta ggaaatggtc tcactgctgg
1801 gtctgtgggg tatgtgtgtg tctgggtgtg tggctactgt ctgcatcctc ctccccccta
1861 cagcctcccc gcctcccctc cagccaccc cc cctcccctca
1921 gctcccctag accctcccag agcctttatc agggagctgg gactgagtga ctgcagcctt
>'rAC3-Exon 1(2001-2117 -> 117bp)
(T/C)(dbSNP:2291855)
2101 ACAGAGCTGC TCCACAGgta ggcaagtggg agaatgctgg atggaccaga
gctggcacca
2161 ggggacagga gccagcgtca ggaggga cagcctctga taggggagca
2221 ggggactggg aa=ggtgagca caaagcacct gtagggccga gagctggttg gtgtttggag
(G/C)(dbSNP:2291856)
2281 cctgtggcta cagactcatt ctttcatacc agaaagtttt tgcctaagtc ttgggattat
2341 ctagtactgg aaaatagcat ccaggatccc tcctccagct gactgaggaa acagaccagt
2401 ccatgtccta caaatctatc atctttcttg ggagctagag tcctcctggc aceactatag
2461 cattgcacat ctcctgggga gatatctgat ggggtagcag ggaaactaag cccaagggct
2521 gtaccccctt ctcagaaata ctttccaccc tctctccaga ccagggcttg gacagtggag
2581 ttgggggctg gggaagcagg gtC:J:lL'C Cl .aatgtct cttgtgtctt
2641 cacccatgct gtatcttcct cttctctcct ttacctgagt cctgtccctt tgctctccca
>TAC3-Exon 2(2702-2820 -> 119bp)
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•
2821 gtaagtctcc cctggcagag tactggggac atcacgggaa cttgggactc tgcctgtctg
2881 tggggtgggg gggttgtccg tcagagggca ttttgcctcc
2941 ctttggattt ctttgtttct ctggtccttt catgttccca ctgtctccag gtgtgtttgt
3001 gtctctgtat ctctgcatgt ctttgacacc ttgtacataa aaggtgccct acaaatatgt
3061 tgtttggtgg gttgattgat gggagacttg gtgattggat ggtactgtga ggggtgagct
3121 agggtggtct aaggctctct atagtctacc tcaggtccct ttgcaaggga cagatctctt
3181 ctatttcctg gatggtatga aacagtcaga atttctttcc caaatggtta tttgtgtgct
3241 attttaccta tcagttatgt gtattgtttt attttcaaaa tgcaaataaa ttcccttatc
3301 ttttgctcat ccacccccag taacctcagg tgcttctaag atcccaaccc cttccttctt
3361 ctcttttctc ccttgcccgc etetateete tgcttagtca ggataggaaa acaacaacag
3421 caaaaaaacc agattgagcc tcgatttcca cagttccttt acgaaaaaga ataggaattg
3481 tcagggtagg ggtacagggg gaggataggg aggaagtctt ttcaaggttt tgaaatgaca
3541 gcaattacat cggtacaaat gcttttaaga tgattgcggg tgggacttat tacaaattca
3601 atgtgtgaag tttaactgcc tcttcagctc aaatctgttc agcatctcat tataggaggt
3661 gggcagagta ttcaacaatt tgggaaaagt ggctgcctga acaccacatg ctgggccaag
3721 ggagttatca ccagggcagc cttgcaggtg gcagcagttg tgccatatcc aaaaggccag
3781 aaccgttaaa aaaaaaaaca cccaggggag tgccaagtat gggctggaca ccgtttggag
3841 ccacaaagtt ccagcccagg atagttagag tatctgagtt cttctgagac aaacttgttt
3901 caagaccttg gccaatgaga tgtcccctct gcccctcttg gtcaatgaat gagaogggatt
(G/A)(dbSNP:2122694)
3961 gccatcctac cccttctcct tgagagtctg tgaggatgag ggaaattggg gcaggaagag
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4021 ggtagtacat aggtgtgcct aggcaactgg gttggtatgt gtgggggtgt gttctgtgta
4081 aatgcacttc tgtgtgtgca caacagccga aggatgcctg ggttctggaa agagaggcgc
4141 tgctgagact tgagatttga gatgaaaatc tccagccatg atcattgtta ttgtctctct
4201 gcagctgcaa ttaactggct gtgtggtgtg tgcccaccac cctgctgtac gcaagttgct
4261 aaaaaaaaaa aaaaaatcac agggacaatc aagagcccgt gctgggcaac agctctagaa
4321 cttgggattc agttgtggag agaagaagac gtgccttctg agcatgttgc cttcctggaa
4381 ttctagacct agggccaaaa gggagaggga gagaaaacta gaggcggaaa geeatggaga
4441 atagagaaag aggtggtgga aaacagggag agaaacatcc atggacatcg tgcagagtgg
4501 gggaatcaca ggtgcagatg tgtgcctcca atctcaccat gcatgtgaat cacctggggg
4561 gctgcttaaa atgcagattc tgtctcagga ggtctggggt aggaacaaga gtctgcattt
4621 ctaacaggct ctgtgtagtg ctggtgttgc tgttggtcca caggtcactc ctgg.l::CL .
tgtgaa ccagaggaaa ctctgaaaga aatagggtgt cggattcagg
4741 atgggctcag gaagaggctg tttcttgtgg gaaaaggatg agtggatccg ggtgggagcc
>TAC3-Exon 3(4833-4926 -> 94bp)
4801 tcctgcctca cccctctttg tttcttccct
CAGCTGCTCC
4921 GCA.CA.(Jgtag gaggcggccc taggggagag gggaatgagg ggcaggattc
ga gate :l.i.))! ggggga tagcttagtg aatcggtgag
5041 ggttgtgatc tgaaccccgc tctcatcact "ttccaacttc actccccatt tagacatctg
(5071 )(branch site - YNYYRA Y)
>TAC3-Exon 4(5116-5145 -> 30bp)
510 1 ttcttggttt
taccctcttc
5161 tccctcccta tctcttgcca cttgcccaga gctctgtggg gcattgggcc caggggccat
5221 tttgtccagc cccttctcac ctggtacaaa )!c:.c(cactg ctcagccaac
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5281 ctttcctgaa agggagaggc catccagaac taggaggaag ctggtgtgag gggcatggtg
5341 ggctctccct ctgctggctg gtccttggaa aacaagggga tctcttcgtg gccctgaaaa
5401 ttccaaatca ggcacctgct agagcagaaa attcttgaaa tgtggaggaa ggaaaggtga
5461 gcagagagag tgggtttagg ggaggcactt gctaa.
5521 aaaaaggaac agagaccaga aacccagtct cagaagtgtt gacccatgtc tggggagatg
>'fAC3-Exon 5(5629-5682 -> 54bp)
(5601)(branch site - YNYYRAY)
5641
AGgtaggagt gtgtggaggt
5701 acagtggaag ggcttagggt actggcagag tatgacagaa gtcacgtgcc tcatatttgt
5761 caeca ( i rtcttac cttcagtgag ggttcctcgg ccccttcatc
5821 ccaatcagct tggatccaca gga=aagtctt ccctgggaac agaggagcag agacctttat
(G/A)(dbSNP:733629)
5881 aaggtagtcc tgttgcagct gggaggaagg atagggagac tctgcttcca ccccagtctc
5941 ccaactctgt ct: dccageeet ttgctgttgg atcagggtgt
(1'/C)( dbSNP:2270734)
>'T'AC3-Exon 6(6052-6126 -> 75bp)
6001 agttcacatt cagaaagatc cctcttactt acactgttcg ctttacccta
6121 AA'IIIIGgtaa ggattgttca ttagagaggg gagaggggac tggggagggg gctgtggggg
•
6181 ttgccagctg tgcattt. ;;i taaa gctcatagat ttgccctgaa
6241 atacactgcc aatgcccagc acactgtcgg ccaaacacaa agacacttag aggcacgtgt
6301 gtttgtacac atcccccgtc tttcatctct ttcctctgga tcatggacgg cagctgacta
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6361 ttgagcagga gtgagtgttg ggagatgagg agagaggggc ttccccgatg ggcaatttct
6421 gttgtttgga cttcattctt ttgtaatcta tgcaaaaaga tggagaaatt attatctgat
6481 aattacaaat accacaacca attcacaggc aagcatttgc ctcccaggca ggctgagcct
6541 ttcaaatcac tcagaatcct gggttacggg gcccagaagg tagtcataca caaggatgat
6601 tcaggaagaa atgcaaggaa ctctgaaatc taatggggat tagcaggaaa ccatatctga
6661 atctctcttt agcataatga ataagaacaa tggeetgaat gtgaatcctg gatctgccac
6721 tctatctgta tctttttggc caaggtacat atcctcctgt gcttcagttt cctcatctga
6781 aaaatgaaag tgataatagt atctcacagg gttgtggttt tgaggattga gtataggtaa
6841 agtgttcaga acagtgccgg gtgcacagtg ctgtgtgcca attttatgat aattgtccca
6901 gtttgggagg tatgggggat gtcctaatgt ttcccctgac tggctctgtc tggaccccag
6961 gcctgagtgg gctgacaaat tcctcacttg gtatgcgagt gtaagagtcc cccagggaag
7021 tgtctagtca aaacacgaac cttccgcctt gacactgtct tcccacacac agcaagagca
7081 gctccaccaa tggctttctt ttcactagct tccaaagaat tggggtggag ggagtgaaaa
7141 ggagagggag agagattggg aaggctcgta atcatggaga gcctcctgct tttctctctg
7201 tgtccctgtt acccatactc actggtctca aggtggcacg cccaagaccc aaggagetgg
7261 tgcttgatga tgctgcctgt gcatgaattc ctgggaccag agactgagtc tggcccccca
7321 tttagtgttg ggtgagaggg cacaaagagc tataataact gtaacttgct gattacatgg
7381 tagttactgt atcattttgc tctcattaga tggttatttc agtcctgccg acggccagat
7441 aattatacga gcagctatat ctggatgaca tactctgctc cagcgttatg cactggccat
7501 aaagataatt acagtgcaat tttgctatag tattttatac aaatggcaaa aacaagtgca
7561 ttgtggaaat ctacttttaa tgcttgtttg tgcatccagg ctctttcaga gggacccata
7621 attgcagctt tcataatctt accattgagg gagcattccc aacctgttag gtgtcaggca
7681 gaataggaca taaggtttct gggagctggc atttaaagat tagatgagat ggatcaacac
7741 agatcattgt gtcatctgat ttcattcatg tgaaactgta agtaatccct gggcctgtgc
7801 ttcctctggg aggtttctgg gaagaggagg aactggataa ggcaggggga gcattcatag
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7861 tagggcacct tgggcagggc tgtgtgtgtg tctggctcat ggtggtgcta ggatggcatg
7921 aacttggttc ctacatcttt ggtccacatg ggccccactg gccatgcaca caggtgtgta
7981 gagtaatgta aatatggcag ctgggaaggt gcaagtacct gcggctagga gagttccatc
8041 ctcaggccca aagcctggag ggcaggctga gggtcaagac ttgttctttc ctctctcaca
8101 gacgcctctc cccttctctc ctgctgccac agcaggtttt cagtgggact tttttacavc
>I'AC3-Exon 7(8216-8502 -> 287bp)
8161 ttttttttt gttttgtttt gttttttgtc
(S 169 )(branch site - YRYRA Y)
(8240-8377)(STS:G 11486), (8241-8429)(STS:TIGR-A004P28)
8521 tttacttgtt tggttggtgg gtttttctgt tccttgactc
8581 cacacatact tatgatacac acacttcata tttaaatgta aataacttta catatctttt
8641 tgtatatatc tatttcctga acagtgcctt acacagtgct ttgcacgatg agtatcagat
8701 ttatttagtg attaaaataa atacacgaat ttggaagatg gtttctaaca cacaaagatt
8761 tttacagacc agttttagat aaagaaaaaa caggccgggc ccggtggctc acgcctgtaa
8821 tcccagcact ttgggaggcc gaggcgggtg gatcacgagg tcaggaggtc gagaccagcc
8881 tgaccaacat ggtgaaaccc cttctctact aaaaatacaa aaattagcca ggcatggtgg
8941 cgcatgcctg taattccagc tacttgggag getgaggeag gagaatcgtt tgaacccagg
9001 aggcaggggt tgcagtgagc cgagatcacg ccactgcact ccagcctggg caacaagagc
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9061 aaaaaactcc gtctcaaaac aaaacaaaca aacaaaaaaa acaataaaaa aagaaaaaga
9121 aaaagaaaaa aaatattcag aatgacttgt attactagga tgggtctggg agatattcat
9181 tcctgaatct gaccctactt aattagagaa ggaggtgggg atcaaggctg teeggagace
9241 cagccacaga ggaggacaaa tctatgaccc tatacaattt ttttgtctcc aaatgctgag
9301 cctgggttct gtgacagatc ctggggatga aatgatgact catacacaga gtttacagtt
9361 tagcagggct gtggacaagc aaacagaact tgatccagct aggatgggat gtggacaggg
9421 aagttactac cgaggccaag aaagagagga gcagatatct tcaccgttaa ctggctgcct
9481 tagttattat aaagggaaaa catttatete ccactcctct ctaaagtgcc tgttaccagc
9541 tcctgcagct ctgacttaac agtccccaga atgtgtaagg cacttacatg tggtatgcat
9601 gggtatggat gtcttttact aatctatgat gtcaactatc acccgccatc ctaagggggg
9661 ttctgtaccc taatggaaca gccagtgaaa tcctcaggct ccttatctta gcgtggtaca
9721 ggggcctttg ttatgcccct gaattgcact gataaaacat caacacatag atttcccaag
9781 gcagtgtaag gacagggcca cagagccaga ggccacttcc tgcagtcctt teattetagt
9841 gaaaattcta tcttcctaca gcctgacttg gggccacttt ggaatgacag ctgtatagtg
9901 gggggcgggg aaaggaggga atactcaccc tagtattact tatgtcagct ttatagccag
9961 aggtcaaaga atgcccccac cccagagcct agaccctttt tccagtgagt catctctttg
10021 acttttcaaa attatctatc tatagggctt aaaactgggg acacttttgc agagtctagg
10081 ggctttctct gggtcatgaa agctacaaga gttggttctg ctcagacttg gtgggagtta
10141 ggcttatagg ctgagatgag acaattgctt tgcaagtagg aacattaagt gcagaaagat
10201 tgctctctag tgggactgac aaaaattgca gtactgggga ctccagaaaa aaatgaagac
10261 aaatgttaag ttagattcct gtgtttgtac ttgaagaatg tgtgaaggga tcctgaccct
10321 ccctttcctg ttgtaaaaca gttgatgcct aaagagatct ggtccacaag acettgacta
10381 aattcctggc cctttcttct ccatttaact ttgtatatgt ttgttattgt gactatatgg
10441 tgatttactt taaaaagact tcagtataag tggtatatac tttcacctgc gtcttttgga
10501 tg
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Key: exon =
primers = grey.
start and stop codons =
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Appendix F
TA CR3 Gene Annotation
Annotated using mRNA sequence:
LOCUS NM 001059 1755 bp mRNA linear PRJ 20-DEC-2003
DEFINITION Homo sapiens tachykinin receptor 3 (TACR3), mRNA.
Annotated sequence file:
LOCUS NT 016354 136349 bp DNA linear CON 19-FEB-2004
DEFINITION Homo sapiens chromosome 4 genomic contig.
ACCESSION NT_016354 REGION: complement(29002755 ..29139103)
VERSION NT 016354.16 GI:3753991O
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 136349)
AUTHORS International Human Genome Sequencing Consortium.
TITLE The DNA sequence of Homo sapiens
JOURNAL Unpublished (2003)
FEATURES Location/Qualifiers
source 1..136349
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db xref="taxon:9606"
/chromosome="4 "
ORIGIN
1 geaggagaat caggtaggga ggttgcagtg agccgagatg gtggcagtac agtccagctt
61 cggctgggca tcagagggag accgtggaga gagagggaga gggagacggt ggggagaggg
121 agacggtggg gagagggaga gggagaggga gagggagagg gctaaagtac tttcatctca
181 ggacttctca gatccttttt ttccttccta tttcttaatg tgaaaaaata ctgctagact
241 ctaggcttca agaatagaat tcatatataa ctgcttcatt gctatactcc cagtatctgg
301 catagcacct ggaaagaagt atgctaatac atagctaaga aatgatagac aatgaattat
361 cactgatccc tcttgtggtc aagggagatt ctcagtaggt aaggcagatt gagaaggaaa
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421 gccatgccct gaatgeetee cttcctctga aaggaataaa tttttaaact tctttcatta
481 tatctaattc catcattate ctttttttcc ttgtcatatc ccctctactt tgtataagcc
541 caatgaaggc aaaactgaaa aattaaaatg tttgttgtaa gtattacaag gaaagcaaca
601 gtaaaatgag tgtatttcta cacaactaag taatttttca gcttcaaaaa tctgatcaaa
661 acatgcttaa ttaccaaacc accacataac ctattttgta attttgagta agcaggtgtg
721 teatatggag atatattttt aatgtctttc taattgcatt gggaaaggaa gaggctttca
781 tttgtaacaa gcaatttcta gatgatgaat tagaacaaag aagtaatctt tcaaaagaaa
.....(continuous)
2821 gcaggacgct cagttctcca gcctgtgccg ggcagctggc accctcccta I\cgtgtgatgt
(G/C)( dhSNP:3 733631)
2881 gactcgataa cccttaatct cgggaggatc tc.: >ccgcaagc
2941 geetetgaga aagtgcagct gttgcccctt agccccagct gcatc=cccta accagcaggg
(:2l)gÓ)( branch site - YNYYRA Y)
>1 ;\CI\3-1':\.011 ](3001-3()89 _;> 689hp)
3001 ATTGCAGTAT CTTTCAGCTT· CCAGTCTTAT CTGAAGACI\TC
CGGCACCAAA GTGACCAGGA
CT/C)( dbSN P:3733632)
3061 GGCAGAGAAG· AACTTCAGAG GAGTCTCGTC TTGGGCTGCC
CGTGGGTGAG TGGGAGGGTC
3121 C
CAGAAACCTG GATAGACGGG•3181
>GCTGC CGGGGCGGCC
3241
AAGCTGGCAA CCTCTCCTCC
3301 TCCCCTTCCG CGCTGGGACT GCCTGTGGCT TCCCCCGCGC
CCTCCCAGCC CTGGGCCAAC
3361 CTCACCAACC AGTTCGTGCA GCCGTCCTGQ CGCATCGCGC
TCTGGTCCCT GGCGTATGGT
3421 GTGGTGGTGG CAGTGGCAGT TT"TGGGAAAT CTCATCGTCA
TCTGGATCAT CCTGGCCCAC
(3443-3620)(STS:RH70865)
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3481
64321 actattgaaa cg . cattt caaactctgt tataaagaaa
> I/\C1\.'-[:\.on 2(64414-64602 -> 189bp)
64381 accaatgaaa tggttttgtt tgtttttata
ATCCCTTGAA
64441
AGTATTTGGA TTCTAGCATT
64501
64561
ACgtaagtta attctctatt
64621 atggttttca attcagttta tcaaacattt
.....(continuous)
65281 taacaaatgg tgcaaa=taat ggttgccatt taaagcagtc attttatcta cctttgctct
Cf/G)(dbSNP:3822290)
.:.•·i:l..;aattaa
65341 acccaaagtt cagatttttg aacaaaaata ttaggaggca cttatttaag gaaaatcaga
65401 cagctcatat taaactgagt accctattca tattattaat acatcttaat tgtatgataa
65461 tgttatcatc ttcaaattat ttgttgactg aattatttcc tcattgactt taaatcaata
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65521 cttagtaatc tactgagaaa tggaaaggca aggatattta agattcactt tacaaaaaac
65581 aaaacaaaa+c aaaaaaaaoca ctggtatgga gaagaccgtt ctaacaaact ttttaattac
(A/- )(dbSNP: 11445973). (C/- )(dbSNP:3839188)
.....(continuous)
66361 atgtagaaat aactcttggt agttttaatt atgattta cc
((Jó417)( branch site - YNYYRA Y)
I R3-Lxon 3(66473-ó6623 -> 151bp)
66421 aatatttcat tccaataagg tcttcagcat gtgtttttct tatttttcat agTIACCATA
66481 TTATCGTCAT TATACTGGTG TACTGTTICC CATIGCTCAT
CATGGGTATT ACATACACCA
66541 TTGTIGGAAT TACTCTCTGG GGAGGAGAAA TCCCAGGAGA
TACCTGTGAC AI\AGTATCATG
(G/A )(dbSNP:2276973)
66601 AGCAGCTAAA. GOCCAAAAGA AAGgtactgg tccatgttgt ttacctagca
tttgtatagg
66661 ttatggtata tcagaaagaa aagc
.....(continuous)
naatacaa tatgatctga
131041 ttaactgt aataagcta ttggaactat tatgagtatt
r\3-1 xon 4( 131134-131330 -> 197hp)
131101 atatttgtca aaaatgactt tttttcttta tagGTIGTCA AAATGATGAT TATTGTTGTC
131161 ATGACATTTG CTATCTGCTG GCTQGCCTAT CATATTTACT
TCATTCTCAC TGCAATCTAT
131221 CAACAACTAA ATAGATGGAA ATACATCCAG CAGGTCTACC
TGGCTAGCTI TIGGCTGGCA
131281 ATGAGCTCAA CCATGTACAA TCCCATCATC TACTGCTGTC
TGAA TAAAAG gtaaaaacaa
131341 aactaocgaaa tgcaagttgc ttgtcacacc
(T/C)( dbSNP:6822961)
131401 cattttcttg gttcaaattc aaaatgcaga aggaagggaa aatttaagaa ttcactgaga
gttgttc
131461 gaggcacagg ctttatcttt caagaccccc atacacactt tataaagcat cccacattaa
131521 taoattagatg ccccaaataa tgatcttggg gttctaactg gatgattctt ctatgggcca
(G/A)(dbSNP:6847994)
131581 acttcttcct ccaaaatctc agaattttac ctgccaaaga aaaagaagtg ccctcatgat
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...... (continuous)
132601 ctgggaatca atgcttctca ttaatgggaa attaagattc aattcaaaca agaactaaac
132661 gactaacaac agtactgtga cataaattct aagagtctgg ctaaaaacca aactcaaaaa
132721 ctgagttgtt ataactgcct tav ' .', tgaaaga catatctgct
.» I \CW1-Lxol1 SI 132X23-133349 -:> 527bp)
132781 tgaaaaaata actttttctt tctgtggcct gcttttcctc agATTTCGAG CTGGCTTCAA
132841 GAGAGCATTT CGCTGGTGTC CTTTCATCAA AGTTTCCAGC
TATGATGAGC TAGAGCTCAA
132901 GACCACCAGG mCATCCAA ACCGGCAAAG CAGTATGTAC
ACCGTGACCA GAATGGAGTC
132961 CATGACAGTC GTGTTTGACC CCAACGATGC AGACACCACC
AGGTCCAGTC GGAAGAAAAG
133021
133081 CGCCACTTCA AGmCATAA. QCTCACCCTA TACCTCTGTG
GATGAATATT CT'1IIIITCCA•133141 TTTCCTGAGG TAAAAGATTA I\GTGTGAGACC ATCATGGTI\GC
CAGTCTAGGA CCCCATTCTC
(133161-133273)(STS:WI-9174), (133179-133328)(STS:WI-18877)
133201 CTATTTAI\CCA GTCCTGTCCT ATATACCCTC TAGAAACAGA
AAGCAATTTTTAGGCAGCTA
(T/C)(dbSNP:2765 )
133261 TGGTCAAATT GAGAAAGGTA·, GTGTATAAAT . GTpACAAAGA
CACTAATAAC ATGTTAGCCT
133321 CCACCCAAAA TAAAATGGGC TTTAAA1Tfa ttctttgaaa actctaaatt
attatatgca
133381 atgaacaaaa atatsrtc ') .• cc agtetatete atttacaaat
133441 tgcaatatac atttgtgaca ttaaaatgat atatagtttt tccaagagat taaagaatct
133501 ttaaaacata atattgtaag tgaagggaaa caaaatctgt ataaaatctg tataaaatag
133561 gcttttttgc ctagagatat aaaatgggaa aaaaagttaa atgattcatt ttcccactag
133621 agtaatggaa aattaacctc aagaagtagg aactgaaaat ctttgctcaa gaaaactcat
133681 tttgtagaat gtaaagattt aaagatttaa agatttcttc catggcattt aactgaaaag
133741 gaaatctagt taaatcatta ggcaaatgta tatttcattc tcttgatttt ttttctgaga
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133801 aagtgaaatt ttaaaaaatt atatactttt tgaccattac ttatttttga ataccaagct
133861 aaaaagtagt cagttaagac cctaaaaata tgaagaaaat tcctatcatt ttttattttt
133921 cacagatttt ttaaatagct agattataaa acagtaaagg tacattccaa taaatagagg
133981 aagaatacta tttatgttct cttcctctcc cctcactgaa aatagaataa ggactaggag
134041 aaaatatctt caaaggcaac tccttaggga aaaaaagtca caagtgtgac aaaagoactat
(A!C)(clbSNP:7438251)
134101 atggttgaaa aataccaata tatgttacat atgagtaaac taggcaaggt gtagacaagt
.....(continuous)
135841 atcagaaaaa ttcaaaatat ttttaaacaa atatgaaaga atcaaaaagg cttacatcat
l35901 tgtaagtatt ctcrttr'aaa caaaatacat taaatcaaaa ataaacattg cttactattt
(A/C)(dbSNP:4642251 )
135961 tgcatctgga caaagtacaa gatattgaaa ttacctgtat gggaaaatat taaagcggac
136021 ataattgtta cagaattcac tctcacactt ttttattttt taccaagtac agcacactgt
136081 tgcattattc catcttctaa cttcatgatg gtgacatttc tgacccagca getgaatte-a
(GIA)( clbSNP:6533099)
136141 tgtccttttc caaatcctgc caatgtctta gaaacagtga actgagcaat ttcagagtga
136201 accccgccct tacaaagcac ataaagaata ccaagaagct tggtateaag cctatgaaat
136261 acaaaataaa tgtgaaaaat aaatgctggc cagctcaaca tttgaattta gtttttgcaa
136321 atgcaaaatt tcctctaaaa atttatgat
II
Key: exon =
primers = grey.
start and stop codons =
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Appendix G
Recipes and Protocols
PCR primer dilutions
20.0Jll 100pmol/ ul stock
180.0Jll dH20
200.0Jll lOpmol/ul primer
dNTP mix
5.0Jll each stock solution (lOmM G, A, T, C)
980.0Jll dH20
1000.OJll
PCR Protocol Key: F = Forward
R=Reverse
5.0Jll lOxbuffer
10.0 ul dNTPs
3.0 ul MgC}z
1.5 Jll F primer
1.5 Jll R primer
0.1 Jll BioTaq
1.0 ul DNA
50.0 ul
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PCR cycle conditions
9YC 2 min.
94°C 30 sec.
Ta 15 sec.
ire 1 min.
x 40 cycles
ire 5 min.
Multiphor Solutions
3.4%C, 40% stock
58.8g Acrylamide
1.2g bis-Acrylamide
Make up to a final volume of200ml with distilled water.
0.75M Tris Formate buffer
90.8g Tris
pH to 9.0 with Formic acid
Tris Borate buffer
125.9g Tris
17.3g Boric acid
Make up to 950ml with distilled water and pH to 9.0.
Add 50111of 4% Bromophenol Blue solution and make up to a final volume of IL
with distilled water.
41% Glycerol
4lml Glycerol
Make up to final volume of 100ml with distilled water.
10% Ammonium Persulphate
19 APS
lOml SABAX water
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Restriction Gel Mix
5.3ml 3.4% PAGE mix
8.5ml Tris formate buffer
3ml 41% glycerol
200~1 APS
20~1 TEMED
Loading dye
47.5mI95% Formamide
0.16g 100mM NaOR
0.125g 0.25% Bromophenol Blue
0.125g 0.25% Xylene Cyanol
Make up to a final volume of 50ml with distilled water.
Silver Staining Solutions
Fixing Solution
Ethanol
acetic acid
distilled water
per 300ml
30ml
l.5ml
268.5ml
Staining Solution
Silver nitrate
Distilled water
per 300ml
0.3g
300ml
Developing Solution
Sodium hydroxide
Distilled water
Formaldehyde
per 300ml
4.5g
300mI
1215~1
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Appendix H
Table of candidate genes already screened in study patient cohort.
Sample MTHFR MTHFR AGT eNOS Prothro tvL
No. C677T A1298C M235T G298A G20210A G1691A
1 1 1 3 2 1 1
2 2 1 3 2 1 1
3 1 1 3 1 1 1
4 2 2 3 1 1 1
5 1 1 3 2 1 1
6 1 1 3 1 1 1
7 1 2 1 2 1 1
8 1 1 3 1 1 1
9 2 1 2 1 1 1
10 1 2 2 1 1 2
11 1 2 3 1 1 1
12 2 1 3 1 1 1
13 1 1 3 1 1 1
14 1 2 3 1 1 1
15 1 1 3 1 1 1
16 1 1 2 1 1 1
17 1 1 3 1 1 1
18 1 1 3 1 1 1
19 1 2 3 1 1 1
20 1 2 3 1 1 1
Key: AGT = Angiotensinogen; eNOS = endothelial nitric oxide synthase; Prothro =
Prothrombin; NL = factor V Leiden.
1 = - / - (homozygous wild-type, no mutant allele); 2 = + / - (heterozygote status);
2 = +/ + (homozygous mutant).
Ten of these patients belonged to the Group H and the other ten were from the Control
group (as previously described).
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Appendix I
These data have provisionally been presented at the:
i) South African Genetics Society conference (April 6_9th April, 2004) and
the
ii) University of Stellenbosch Health Faculty's "Academic Yearday" (August
19th, 2004) and
Data will be presented at the forthcoming:
iii) International Society for the Study of Hypertension in Pregnancy (ISSHP)
in Vienna, Austria (November 14_17th, 2004) and
iv) South African Society for Human Genetics (SASHG) conference
scheduled for April, 2005.
v) A manuscript describing the findings of the study and incorporating the
biochemical measurements ofNKB is currently in preparation.
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